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CHAPTER I 
 
 
INTRODUCTION 
Selenium as an Essential Trace Element 
Selenium (Se) is an essential trace element for humans, and its appearance in the food 
supply is closely related to soil selenium, which is highly variable  [1].  For example, selenium 
was first recognized as an essential trace element in 1957 when it was discovered to be crucial as 
a component of Factor 3, which prevented liver necrosis in rats [2].  In 1973, the University of 
Wisconsin reported Se as a part of glutathione peroxidase (Gpx) [3], and in 1985, phospholipid 
hydro-peroxide glutathione peroxidase (p-Gpx) was identified as a second Se-containing enzyme 
[4].  These two enzymes generally characterize the biochemical functions of Se such that the 
presence or absence of Se affects the underlying mechanism by which Se contributes to redox 
balance [4].  In animals, Se deficiency results in pathological conditions manifested as defective 
growth, hepatic necrosis, myocardial degeneration and muscular dystrophy [5].  In humans, Se 
deficiency takes on symptoms related to the function of Se in the body.  The symptoms range 
from bone and muscle pain to dry, flaky skin [6].   
High levels of free radicals induced through deficiency of Se leads to reactions 
contributing to pathologies of diabetes, cardiovascular disease, hypertension and related 
complications [6].  Se is crucial for the antioxidant activity of Gpx, which catalyzes the 
scavenging of reactive hydrogen peroxide and lipid hydroperoxide [7].  It is also important in the 
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conversion of the thyroid hormone thyroxine (T4) to triiodothyronine (T3), as a component of the 
selenoprotein 5’ iodothyronine deiodinase, the enzyme responsible for the conversion [8].  Low 
Se intake has also been associated with Kashin-Beck disease, a disease characterized by endemic 
osteoarthropathy affecting both bones and joints with a typical onset in the first or second decade 
of life [9, 10].   
 Despite its requirements for enzymatic function, excess Se may lead to a toxicity 
associated with negative effects.  Short term exposure to excess Se consumed through diet in 
animals results in abnormal posture, unsteady gait and eventual death. Livestock exhibit 
blindness, weak legs, paralysis, dullness, anorexia, weight loss, ataxia, and dystrophic hooves 
from long-term consumption of highly seleniferous grasses and crops [11].  Humans living in 
areas with excess Se in the soil developed changes in their integumentary system manifested as 
dermatitis, hair loss and nail changes [12].  These changes were observed at an intake greater than 
16 times the optimal level for the recommended dietary allowance (RDA) [12].  As a result, early 
research on Se focused on the consequences of excessive Se intake.  Current research, however, 
also includes focus on Se deficiency and the resulting pathophysiological conditions after Se was 
identified as an essential nutrient for balancing the redox system [13].  The emerging evidence is 
promising in support of the importance of Se in the prevention of chronic diseases, including its 
impact on bone health [13].     
Selenium and Bone 
Overview of Bone 
Bones constitute a large part of the endoskeleton of vertebrates and support and protect 
various organs of the body.  Bone consists of osseous tissue that provides rigidity and a coral-like 
three-dimensional internal structure.  This tissue is relatively hard and light weight, formed 
mostly of calcium phosphate in the form of calcium hydroxyapatite (Ca10(PO4)6(OH)2) [14].   
Osseous tissue houses marrow, endosteum, periosteum, nerves, blood vessels and cartilage [14].    
Bone is not uniformly solid but consists of two main compartments:  cortical bone and trabecular 
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bone.  Cortical bone is compact (5-30% porosity) and makes up the outer compartment of bone, 
while trabecular bone makes up the interior and is composed of a network of rod and plate-like 
elements that make the overall tissue lighter and allow room for blood vessels and marrow.  
Trabecular bone accounts for 20% of total bone mass, and cortical bone accounts for 80% [15].  
Aside from a structural and protective role, bones are important in movement, blood production, 
mineral storage, growth factor production, and fat storage [16].   
Cellular Structure of Bone 
Two types of bone cells constitute trabecular and cortical bone.  Osteoblasts descend 
from osteoprogenitor cells and form bone.  They are located on the surface of osteoid seams 
(narrow regions of newly formed organic matrix) and make a protein mixture known as osteoid, 
which mineralizes to become bone.  Osteoid is mainly composed of Type I collagen secreted by 
osteoblasts.  Osteoblasts also produce hormones like prostaglandins to act on the bone itself.  
They also produce other important molecules involved in the mineralization process including 
alkaline phosphatase [14].  Osteocytes are formed when osteoblasts mature after migrating into 
bone matrix and get trapped after mineralization.  Not only are osteoblasts important in bone 
formation and matrix maintenance, but are crucial in calcium homeostasis [14].   
Osteoclasts are the multinucleated cells responsible for breaking down bone, a process 
known as bone resorption.  These cells are located in resorption pits, also called Howship’s 
lacunae, and need to migrate to the site of resorption.  They act by releasing active enzymes such 
as tartrate resistant acid phosphatase to break down the crystal of bone.  They release acids to 
solublize mineral as well [14].   
Molecular Structure of Bone 
 Bone matrix makes up the majority of bone and consists of both inorganic and organic 
components [17].  As mentioned above, hydroxyapatite is an important component of bone, and 
is the inorganic portion of bone matrix [18].  The organic part of matrix is mainly composed of 
Type I collagen synthesized intracellularly as tropocollagen and then exported to form fibrils 
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[18].  Various matrix proteins also make up the organic portion of bone matrix including 
glycosaminoglycans, osteocalcin, osteonectin, bone sialo protein, osteopontin and cell attachment 
factor.  These growth factors are thought to function as growth factors to promote bone 
formation/mineralization but their full function is not fully known [14]. 
Bone Remodeling 
 The purpose of bone remodeling or bone turnover is to maintain plasma calcium (Ca) 
homeostasis, to repair micro-damages to bone from stress, and to shape and sculpt the bone 
during growth.  Bone turnover occurs continuously throughout life and requires osteoblast and 
osteoclast activity in tandem.  Blood calcium is regulated by parathyroid hormone activity, which 
stimulates osteoclasts that breakdown bone and release calcium into blood, and osteoblasts that 
reconstitute the Ca from the blood into bone.  Bone volume is determined by the rates of bone 
formation and bone resorption.  Mohan and Baylink report that certain growth factors may work 
to locally alter bone formation by increasing osteoblast activity [19].  These factors include 
insulin-like growth factors I and II, transforming growth factor-β, fibroblast growth factor, 
platelet-derived growth factor, and bone morphogenetic proteins [19].  Research has suggested 
that trabecular bone volume in postmenopausal osteoporosis may be determined by the 
relationship between the total bone forming surface and the percent of surface resorption [20].  
Bone remodeling is also important in facture and microfracture repair of the skeleton.  Repeated 
stress, such as weight-bearing exercise, or bone healing, results in the bone thickening at the 
points of maximum stress.  It has been hypothesized that this is a result of bone's 
piezoelectric properties, which cause bone to generate small electrical potentials under stress [21].  
Chronic inflammation has been shown to disrupt bone remodeling leading to bone loss [22].   
Bone disorders 
 According to the Institute of Musculoskeletal Health and Arthritis at the National 
Institutes of Health, more than 400 million people around the world suffer from crippling, chronic 
pain of joint disease, osteoporosis, spine diseases and musculoskeletal trauma, and this number is 
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predicted to increase to 570 million people by the year 2020 [23].  Associated risk factors include 
aging, low estrogen/testosterone levels, low dietary Ca intake, and family history.  
Epidemiological studies and studies with animal models have suggested that a deficiency of 
selenium (Se) is associated with bone loss from osteoporosis [23].   
 Osteoporosis is as metabolic bone disease characterized by low bone mineral density and 
microarchitectural deterioration of bone leading to its fragility [24].  About 1.5 million hip, spine, 
and wrist fractures are reported in the United States every year [25].  About 24% of patients with 
hip fractures die within a year after the incident, either from direct complications or due to the 
surgical treatment [26].  These complications include pneumonia and blood clots in the lung [25].  
The estimated national direct expenditures (hospitals and nursing homes) for treatment of 
osteoporosis and associated fractures were $19 billion in 2005 ($52 million each day) and the cost 
is expected to reach $25.3 billion by 2050 [25]. 
 Several factors have been implicated in the etiology of bone diseases including selenium 
deficiency.  Still a major public health concern in many parts of the third world, selenium 
deficiency has been associated with bone loss [27-29].  However, the mechanism in which Se 
plays that role is not completely elucidated.   
Overall Objective 
The long-term research goal is to examine the potential role for selenium supplementation as a 
prevention strategy for chronic diseases associated with inflammation.   
Statement of Problem 
The rationale for these studies is that there is not yet (to our knowledge) a systematic 
investigation of the role of increased dietary intake of selenium as a possible prevention strategy 
for diseases of chronic inflammation.  This research will evaluate potential synergistic effects of 
selenium deficiency and inflammation on bone loss as well as potential beneficial effects of 
selenium supplementation.  In addition, the research model also provides a basis for future 
investigation of nutrient, phytochemical, and drug effects on bone loss due to chronic 
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inflammation.  By understanding the role of Se under normal and inflammatory states, this may 
have a significant impact on the dental, medical, and nutritional fields.   
Objective 
The objective in this research project was to evaluate the effects of selenium depletion and 
supplementation on the skeletal response using an in vivo model of chronic inflammation.   
Hypothesis 
The central hypothesis was that selenium adequate and selenium supplemented diets will have 
better bone quality than selenium deficient diets.  The inflammatory treatment is expected to 
reduce bone quality. 
Specific Aims 
The specific aims were: 
Specific Aim 1: to assess bone microarchitecture of animals consuming different levels of dietary 
selenium.  The hypothesis is that higher dietary selenium will result in better bone 
microarchitecture parameters. 
Specific Aim 2:  to assess bone strength of animals consuming different levels of dietary 
selenium.  The hypothesis is that higher dietary selenium will result in bone that is stronger. 
Significance of the Study 
Selenium deficiency has been associated with osteoporosis in growing individuals [30].  This 
experiment is innovative as the animal model provides a framework for research to apply to 
human models.  The effects of Se supplementation on chronic inflammation have implications on 
human conditions associated with inflammation such as osteoarthritis and periodontitis.  The 
results of the study apply to Se and its effect on bone quality.  If this study is confirmed by more 
animal and controlled clinical human studies, it may serve as a basis for dietary recommendation 
for preventing or decreasing the incidence of a selenium deficiency-related bone disorder.  
Previous medicinal and dental conditions of inflammation that have required continual 
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hospitalization and extended drug therapy will have a potential treatment.  This treatment can be 
adapted to current dietary habits, reducing the cost of medicinal care in the healthcare industry.  
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CHAPTER II 
 
 
LITERATURE REVIEW 
Metabolism of Selenium 
Selenium is classified as a metalloid and has metallic forms such as selenate, inorganic 
forms such as selenite, and organic forms such as the amino acids selenomethionine (SeMet) and 
selenocysteine (SeCys) [31].  SeCys and SeMet are most widely found in plant and animal 
sources in protein form [31].  SeCys is a modified amino acid found in selenoproteins in both 
flora and fauna food sources, playing a role in redox reactions as active centers of selenoenzymes 
[32].   SeCys does not have a free form due to a selenol (-SHe) group that is highly reactive.  Se 
in SeMet residues is largely found indiscriminately within the protein, i.e. a specific codon for 
methionyl is not found in proteins containing Se in the form of SeMet residues [32]. The 
accumulation of Se in plants often takes inactive forms such as SeMet, methyl selenocysteine 
(MeSeCys) and γ-glutamyl-Se-methylselenocysteine [32].   
Selenium as a Component of Protein 
The amino acid forms that Se takes are SeCys or SeMet [33].  The term selenoprotein refers to 
proteins containing SeCys, while proteins with Se as SeMet are called Se-containing proteins [6, 
31].  Se is incorporated within the protein early during the translation of the primary structure 
through SeCys.  This incorporation of Se at this stage 
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protein translation makes Se slightly different among other trace elements [34].  For 
example, both Cu and Zn and other metals are integrated into their respective proteins after the 
primary structure has been formed [34].  SeCys is coded for with a UGA codon in the 
selenoprotein mRNA [35].  SeCys is located in the active site of the majority of selenoproteins 
that scavenge reactive oxygen species (ROS) [36].   Cysteine is structurally similar to SeCys 
except the S atom in cysteine is replaced by Se in SeCys [37].   
Absorption and Transport of Selenium 
Se consumed through food is readily absorbed at a rate that ranges from 50 to 100% [38].  
The major dietary form is SeMet, and it is readily absorbed at about 90% through a similar 
mechanism to that which absorbs methionine [38].  Inorganic Se is relatively poorly absorbed, 
and the mechanism of selenocysteine absorption is not well known [39].  Selenate absorption uses 
a mechanism common to the one used by sulfate.  It depends on the Na+ gradient, and absorption 
is maintained by the Na+/K+ ATPase [40].  Selenate is absorbed almost completely with some loss 
occurring through urine.  Selenite absorption, however, is less consistent, due to interactions in 
the gut.  Once absorbed, selenite is relatively well retained without the partial loss through urine 
seen with selenate [39].  Se membrane transporters have yet to be reported, but SeMet uses the 
same mechanism as methionine [6] (Fig. 2.1).   
Metabolic Pathways for Conversion of Se to a Common Intermediate: Selenide 
Varying forms of Se are consumed through diet to be eventually transformed into a 
common active intermediate for the synthesis of SeCys  [41] (Fig. 2.1).  Inorganic forms of Se, 
selenite and selenate, are reduced by glutathione (GSH) and thioredoxin reductase (TrxRs) to 
selenide [42, 43].  Transportation of Se uses bicarbonate and phosphate buffer systems.  Selenite 
is directly taken up by red blood cells (RBCs), while selenate ions are taken up by hepatocytes 
[44].  Selenite is readily reduced to selenide, in RBCs and intestinal cells [45].  It is released into 
the blood stream and is bound to albumin and transported to the liver [45].  The reduced forms of 
inorganic Se are used to synthesize selenoprotein P and glutathione peroxidase (Gpx) in the liver 
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for release into the bloodstream [46].  The organic forms of Se, SeCys and SeMet, (as 
selenoamino acids) are transformed to selenide by a lyase reaction [47].  β-lyase transforms 
SeCys directly to selenide while SeMet transforms to selenide by a trans-selenation pathway in 
the cells (Fig 2.1).  Excessive Se intake causes the C-Se bond to be cleaved at the γ position by γ-
lyase of Se Met.  This results in the formation of selenide for synthesis of selenoproteins [48].   
Fig.2.1: Metabolic Pathways for Selenium [42] 
 
SeCys is synthesized during protein formation and converted to selenide.  Selenide is 
used to make selenophospate for the synthesis of selenoproteins [49, 50].  This ATP-requiring 
reaction is catalyzed by selenophosphate synthetase [51].  The carbon skeleton required for SeCys 
is derived from serine, and dietary SeCys or SeMet are not used [52].   Serine is esterified to the 
3΄ end of the terminal adenoside of tRNAsec UCA to produce Ser-TRNAsec UCA by seryl-tRNA 
synthases [53].  The next step involves the production of selenocysteine-rRNASec UCA by the 
substitution of serine-OH with SeH from selenophosphate by selenocysteine synthase [54].  
Degradation of SeCys is catalyzed by selenocysteine lyase which releases elemental Se that 
converts to selenide to complete the cycle [55].   
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Fig. 2.2: Differences in metabolic pathways for selenite and selenate [42] 
 
SeMet does not have a specific codon but uses the same AUG codon as Met to be 
incorporated into general proteins until degradation and release (Fig. 2.2) [56].  Once released, it 
is converted to selenide by trans-selenation or directly by the γ-lyase pathway.  The concentration 
of SeMet in total body protein is proportional to the concentration of Se in the food. 
Mammalian Selenoproteins 
 The first SeCys containing protein was discovered in mammals in 1973 [3].  Since then, 
more types of selenoglutathione peroxidases (Gpx) have been identified and characterized [57].  
Glutathione peroxidase protects against oxidative damage by reducing hydrogen peroxide and 
other hydro-peroxides [58].  Phospholipid glutathione peroxidases (P-Gpx) also function in the 
reduction of phospholipid, cholesterol, and cholesteryl ester to prevent cell membrane lipid 
peroxidations [58].  P-Gpx plays a role in the structural function of male spermatozoa and offers a 
plausible explanation for the male infertility seen in Se deficiency [59].  There are also three 
TrxRs that function by reducing thioredoxin and helping to maintain cellular thiol redox status 
[60].  All of these TrxRs are pyridine nucleotide-disulphide oxidoreductases that contain 
selenium [61].  Specifically, these TrxRs catalyze the NADPH-dependent reduction of the redox 
protein thioredoxin [61].  Hill and co-workers compared thioredoxin reductase activity in liver, 
12 
 
kidney and brain of rats fed selenium-deficient and control diets for 14 weeks after weaning [62].  
Liver and kidney of selenium deficient mice showed a 4.5% and 11% reduced activity 
respectively, but inhibition of thioredoxin activity was not seen in brain [62].   
Other selenoproteins include a family of deiodinases (three in total) involved in thyroid 
hormone metabolism [63].  Types I and II are important in the conversion of T4 to T3, while the 
Type III enzyme inactivates T3 [63].  Selenophosphate synthetase 2 (SPS2), is also a 
selenoprotein which synthesizes the Se donor for SeCys biosynthesis [64].  Other selenoproteins 
important in oxidative defense include selenoprotein-W, selenoprotein-P and methionine 
sulfoxide reductase.  Selenoprotein P also serves to transport Se to peripheral tissues [64].   
Selenium Concentration in the Body 
 The total Se content of the human body is estimated from various cadaver studies to 
range from 13-23 mg [6].  Total Se in US subjects was estimated at 30 mg using stable isotope 
methodology [38].  About 60% of body selenium is stored in various tissues such as muscle, 
liver, blood and kidney, while about 30% is found in the skeletal system alone [6].  Immune cells, 
erythrocytes and platelets have a relatively higher concentration of Se in the body [6].  Normal 
levels of Se are reported to be 0.1 – 0.34 mg/L (1.27 – 4.32 µmol/L) for white blood cells; 0.04 – 
0.60 mg/L (0.11 – 7.6 µmol/L) in serum; 0.03 mg/L (<0.38 µmol/L) in urine and <0.4 µg/g (0.01 
µmol/L) in hair [33].  The National Health and Nutrition Examination Survey (NHANES) III for 
US young adults 19-30 years of age reported the mean serum Se concentration to be 127 and 124 
µg/L for males and females respectively [39].  European adults from different countries have 
different values [65] which ranged from 86 µg/L in Sweden, France, and Italy to 43 µg/L in 
Serbia.  Values for adults in New Zealand are reported to range from 62 – 69 µg/L [66].  
Individuals in low Se areas like in China have plasma Se concentration of 11 – 16 µg/L.   
Excretion of Selenium 
 The primary mode of Se excretion after intestinal absorption is urine [67].  Dietary 
intake, if within normal physiological doses, influences the amount of Se excreted in the urine.  
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When intake is excessive, Se tends to be exhaled out into breath in addition to the urinary route 
[68].  Se is methylated sequentially before excretion to produce monomethylated Se and 
trimethylselenonium as urinary and dimethylselenide as expiratory metabolites [6, 68].  The 
concentrations of the two urinary metabolites differ by the Se intake:  at lower dietary Se intake, 
monomethylated Se is mostly excreted while at high level of dietary Se intake, the trimethylated 
form is predominantly excreted [69].  The monomethylated Se in urine is now characterized to be 
a selenosugar (Se-methyl-N-acetylgalactosamine) [70].  Overall, Se is regulated at physiological 
levels by urinary excretion as opposed to other major trace elements like iron that are regulated 
by absorption.   
Physiological Functions of Selenium 
Gpx 
Selenium, an essential trace element for humans, forms selenoproteins that have a variety 
of beneficial effects for the body [6].  These selenoproteins include four different glutathione 
peroxidases (Gpx 1, 2, 3 and 4), which catalyze the reduction of peroxides that can cause cellular 
damage [6].  Gpx was described, in 1973, as the first selenoprotein with clear metabolic functions 
[3].  These enzymes are usually classified in three different forms:  cytosolic, phospholipd and 
extracellular glutathione peroxidases (c-Gpx, p-Gpx and e-Gpx) and have differences in 
structural, kinetic, immunological and electrophoretic properties [71, 72].  Gpx enzymes play a 
major role in protecting cells and tissues from damage by free radicals and hydroperoxides by 
reducing them into their less reactive forms [73].  Both intracellular and extracellular Gpx are 
effective in reducing hydrogen peroxide and other organic hydroperoxides to prevent injury to 
cell membranes [3].  Gpx has been used as a major indicator of Se status at physiological doses.  
The justification for using Gpx as a marker for Se is related to the linear relationship between 
whole blood Gpx and plasma Se when the concentration of Se is below 100 µg/L [74].  When Se 
is depleted at experimental and clinical levels, the plasma Gpx activity is reduced in humans and 
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small animals.  In addition, both experimental and clinical Se depletion have been shown to 
reduce tissue, blood, and plasma GPx activity in both humans and rats [75, 76].     
Gpx1:  Gpx1 is the classic form of selenium in the body.  It is believed to account for 
about half of the body’s total selenium and is found in all tissues, primarily in liver, kidney, and 
RBCs.  SeCys is the active moiety of the Gpx enzyme [77] and Gpx1 has a primarily defensive 
role as it scavenges reactive oxygen species (ROS) generated from oxidative damage to the body 
[78].  A knockout model resulted in mice that showed no apparent adverse health effects [79], 
with the exception of higher susceptibility to a Coxsackie virus [80], and to acute paraquat 
toxicity [7].  The cyclic oxidation and reduction of paraquat in cells, with the resulting in 
production of free radicals of oxygen, leads to lung injury and eventual death [81].   Gpx1 is also 
purported to protect bone and cartilage from oxidative damage by possibly preventing the 
accumulation of H2O2  in the cell [67].   
Gpx2:  This enzyme was first identified from human liver DNA and is enriched in 
epithelium especially in intestine and lung [82]. The primary GPx species found in rat intestine is 
glutathione peroxidase-2, and it is postulated to be active as a peroxide scavenger [82].   
Knockout-mice models of either Gpx1 or Gpx2 show redundancy under healthy conditions.  
However, ileocolitis has been shown to develop with mice that have both Gpx1 and Gpx2 
knocked out [83, 84].   
Gpx3:  Gpx3 is predominantly secreted by the kidney and is the main form of selenium 
found in breast milk [85, 86].  It is most abundantly found in the plasma [87].  The main activity 
of Gpx3 is hypothesized to be protection against oxidative damage in the intracellular spaces 
(mostly in the kidneys) [88].   
Gpx4:  Glutathione Peroxidase-4 is found in high quantities in sperm and testis [89].  The 
reason may be due to the need to reduce the high level of hydroperoxides being generated during 
spermatogenesis as a substitute for glutathione in case of shortage [89].  Possibly Gpx4 may also 
function as a structural protein of sperm [90].  Gpx4 differs from the previous proteins as the 
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ROS species that it scavenges are comparatively larger [89].  Gpx4 is also lipophilic possibly 
destroying peroxides along membranes [89].  Deficiency in Gpx4 was found to be associated with 
increased breakage of sperm mid-piece leading to male infertility [90].  Gpx4 KO is 
embryonically lethal [90].  Additional glutathione peroxidases, such as Gpx5, Gpx6, and Gpx7 
have also been identified, but their functions have not yet been fully clarified.     
Gpx5:  Glutathione peroxidase-5, also known as epididymal secretory glutathione 
peroxidase is encoded in humans by the GPX5 gene.  It is specifically expressed in the 
epididymis in the mammalian male reproductive tract, and is androgen-regulated.  The mRNA for 
Gpx uniquely does not contain a selenocysteine (UGA) codon.  Thus, the encoded protein is 
selenium independent, and has been proposed to play a role in protecting the membranes of 
spermatozoa from the damaging effects of lipid peroxidation and/or preventing premature 
acrosome reaction [91].   
Gpx6:  This enzyme is not well studied and is described as an odorant-metabolizing 
protein, with about 40% amino acid sequence identity to Gpx1. It is expressed in the Bowman’s 
gland of the rodent olfactory system [92].     
Gpx7:  The function of Gpx7 is not well known.  To date it has only been found as a Cys 
homolog which has not yet been well characterized [6].  
Iodothyronine Deiodinases 
 Iodothyronine deiodinases consist of three selenoenzymes and are required for 
metabolism of thyroid hormones [93].  Thyroxine 5’-deiodinase-1 (DIO-1), or Type 1, is 
abundantly present in liver and converts thyroxin (T4) to triiodothyronine (T3) that circulates in 
plasma [93].  When Se is deficient, the activity of DIO-1 decreases and results in lower 
circulating T3 [93].  Deiodinases Type II and Type III (DIO-2 and DIO-3) are present in different 
types of tissues of the body [94].  DIO-2 and DIO-3 produce T3 and are present in brain, pituitary, 
brown adipose tissue, placenta and skin [94].  DIO-3 is important in the deiodination of T4 and T3 
into inactive forms playing a role in maintaining optimum levels of T4 and T3 in the body [95].   
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Thioredoxin Reductase (TrxR) 
Mammalian TrxRs are selenoenzymes which catalyze reduction of small intracellular 
molecules that regulate intracellular redox state contributing to antioxidant defense systems in the 
cells [96].  TrxR1 is located in the cystosol and nucleus, while TrxR2 is present in the 
mitochondria [67].  When Se is deficient in rats, the TrxR activity is less affected than Gpx1 
activity but more affected than selenoprotein P [67].  Loss of TrxR activity may be important in 
the development of the signs and symptoms of selenium deficiency [97].  The discovery that 
made clear the role of TrxR in reducing vitamin E and dehydroascorbate to the 
semihydroascorbate radical further substantiated selenium’s antioxidant role  and suggested a 
potential anticarcinogen function as well [96, 97].   
Selenophosphate Synthetase 
Certain enzymes are postulated to be responsible for liberating Se from its conjugates.  
Selenophosphate synthetase-1 (SPS1) may be involved in recycling selenium from 
selenocysteine, while selenophosphate synthetase-2 (SPS2) might use selenite-reduced selenium 
[98].  SPS is a selenocysteine-containing selenoprotein that plays a role in providing active Se for 
the synthesis of SeCys in mammals.  SPS1 is essential for selenoprotein biosynthesis [99]. 
Plasma Selenoprotein P 
Other selenoproteins include selenoprotein P, which accounts for about 40% of plasma 
selenium and is the main plasma selenoprotein in the body [88].  It was first recognized in the 
plasma of rats  and constituted about 50-60% of plasma Se [100].  It is secreted by the liver [100].  
Adverse liver conditions in hospital patients have been shown to result in decreased plasma 
selenoprotein P [101].  Se deficiency leads to a 5-10% reduction in selenoprotein P when 
compared to control, signifying the importance of dietary Se in regulating selenoprotein P  [102].  
Synthesis of selenoprotein P is given a higher priority compared to other selenoproteins and 
levels of the protein decline less rapidly than Gpx when exogenous Se supply is limited [102].  
There is also the potential of using selenoprotein P as a marker for Se in individuals with 
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adequate Se intake as the level of selenoprotein P correlates with plasma Se level [103].  It is also 
a transport protein in the blood [104].  Decreased level of Se in testes and brain and increased 
level of urinary Se excretion have been shown in selenoprotein P knockout mice suggesting the 
important role of selenoprotein P in transport [88].   
Selenoprotein W 
Selenoprotein W is largely found in muscle and is smaller in size than selenoprotein P 
[105].  Its role is postulated to be as an antioxidant because it has been shown to bind to 
glutathione [36].  The discovery of selenoprotein W came from the investigation of the factor 
involved as the cause of white muscle disease in Se deficient sheep [106].   
Other selenoenzymes important in coping with oxidative stress includes selenoprotein R 
or methionine-R-sulfoxide reductase as it is produced during oxidative burden [107].  
Selenoprotein K and Selenoprotein S are unique, being the only identified selenium-containing 
membrane proteins [92].   
The Relationship of Se with Selenoproteins 
The selenoproteins represent the largest portion of Se in the body and are regulated by the 
SeCys pool [67].  The effect of Se levels on selenoprotein function was studied in rats and 
showed differential expression of selenoproteins based on the Se status of the body [108].  
Severity of Se deficiency leads to significantly lower levels of mRNA for GPX1 activity in Se 
deficient male rats which showed a decrease of 1% to 7% compared to Se adequate animals 
[108].  Severe Se deficiency leads to significantly lower levels of mRNA for Gpx1 and of GPX1 
protein [109].   
When weanling rats fed Se deficient diet were supplemented with graded dietary Se, the 
liver GPX1 and its mRNA showed a sigmoid response with increased response with increased 
level of dietary Se intake [110].  The study showed, when Se intake is higher than 0.1 µg Se/g 
diet, the Se status fails to regulate both GPX1 activity and its mRNA.  In contrast, the liver GPX4 
activity decreased only to 40% of the Se adequate level and reached a plateau at 0.05 µg Se/g diet 
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while the mRNA for liver GPX4 remained not significantly affected by Se intake [110].  The 
activity of plasma GPX3 was also reduced in these deficient rats to 7-8% of the level in Se 
adequate rats and reached a plateau at 0.07 µg Se/g diet [110].  Other studies also demonstrated 
that liver TrxR, DIO-1 and selenoprotein P activities in Se deficiency decreased to 5-10% of the 
Se adequate level [111].   
In conclusion, these studies show obvious differences in level of selenoproteins by Se 
status.  When Se is deficient, there will be reduced levels of selenoproteins [67].  Factors other 
than Se deficiency need to be considered when Se status is evaluated using selenoproteins [110].  
Considering the progress in the sequencing of the human genome and the current scientific 
advancement, mRNA evaluation of selenoproteins might need to be the preferred approach in 
evaluating Se status in the future.   
Food Sources of Selenium 
Selenium concentration in grains and seeds is associated with the variable selenium 
content of the soil used to grow the plants [1].  Food grown in areas where Se is deficient has 
much lower levels of Se/g compared to food grown in seleniferous areas [30].  Therefore, cereals 
and grains range from <0.1 to >0.8 µg Se/g while fruits and vegetables usually have less than 0.1 
µg Se/g [30].  Se content of livestock also depends on Se content of the food they consume.  
Concentration of Se in organ meats and sea foods ranges from 0.4 to 1.5 µg Se/g.  Muscle meats 
contain 0.1 to 0.4 µg Se/g and dairy products contain 0.1 to 0.3 µg Se/g [30].  In the United States 
most livestock are supplemented with inorganic Se and animal foods here have levels of Se as 
selenoproteins closer to 1.5 µg Se/g [30].  Organ and muscle meats are, therefore, good sources of 
selenium.  Pork, beef, chicken, and eggs are the major sources of selenium intake in the U.S. diet 
[112].   Generally, drinking water has insignificant amounts of Se, but well water in seleniferous 
areas may contain higher Se content.   
Human Requirements for Selenium 
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The upper limit and RDA set by the Food and Nutrition Board (FNB) of the Institute of 
Medicine is still disputed [6], because factors such as the type of Se compound, exposure time, 
physiological status, an unregulated SeMet pool, and interactions with other metals are important 
[88].  The expression of selenoenzymes, on the other hand, is regulated by Se status so a 
biochemical approach (instead of dietary intake or tissue concentration or balance study) was 
used to determine the RDA for Se intake.  In 1980, an initial estimated safe and adequate daily 
dietary intake was extrapolated for humans (50 to 200 µg Se/d) from animal experiments that 
assessed Se status  using the activity of  GPX [113]. 
In 2000, however, the FNB of the Institute of Medicine evaluated the level of Se that 
plateaued the plasma Gpx3 for Chinese men and adjusted the requirement for North American 
males to 55 µg Se/d (Table. 2.1). The data from New Zealand was evaluated by the FNB and the 
plasma Gpx activity increase between the group who consumed 38 µg Se/d was found to be not 
different from the group who consumed 68 µg Se/d and the Estimated Average Intake (EAR) was 
suggested to be 38 µg Se/d. The Adequate Intake for infants for Se varies according to age.  
Based on level of Se concentration in breast milk, 15 and 20 µg Se/d is calculated for under six 
months and 6-12 months old infants respectively. The RDA during pregnancy is 60 µg Se/d based 
on fetal transfer and Se excretion in milk (Table 2.1).  
 
Table 2.1: Selenium intake recommendations for healthy US and Canadian populations [113] 
  AGE (years) 
  
0-6 
months 
7 - 12 
months 1 - 3 4 - 8 9 - 13 14 - 50 >70 Pregnancy Lactation 
AI 
µg/day 15 20 - - - - - - - 
RDA 
µg/day - - 20 30 40 55 55 60 70 
AI:  Adequate Intake; RDA:  Recommended Dietary Allowance 
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The recommendations for Se intake in the rest of the world are lower than the United 
States of America which recommends 55 µg Se/d for all persons 14 years and above (Table 2.1).  
The World Health Organization (WHO) recommended Se intake based on Se needed to achieve 
two-thirds of maximum achievable Gpx3 activity [114]. With adjustment for inter-individual 
variations taken into account, 40 µg/d and 30 µg/d were proposed for adult males and females 
respectively which is in line with typical Se consumption worldwide (Table.2.2) [114]. The New 
Zealand study used 67% of maximum Gpx3 activity and calculated a Se intake recommendation 
of 39 µg/d, which was similar to what the value WHO recommended.  
Table 2.2: Recommended nutrient intake (RNI) for selenium (µg/day) [115] 
 
Selenium Interaction with other Nutrients 
Se interacts with several other nutrients that affect the antioxidant system.  Copper and 
zinc are part of superoxide dismutase (SOD), and iron is a component of catalase [43].  Se also 
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interacts with vitamin E in minimizing lipid peroxidation [116] and with vitamin C as TrxR 
catalyzes regeneration of the reduced form of vitamin C from its oxidized form, dehydroascorbic 
acid [117].  The role of Se in iodine metabolism makes it an important nutrient in thyroid 
hormone synthesis [118].  The effect of iodine deficiency is exacerbated with concomitant Se 
deficiency.  Se dependent enzymes iodothyronine deiodinases are important for conversion of T4 
to its biologically active form of T3 [63].  
Techniques of Determining Selenium Status 
The common techniques for assessing selenium status include measurement of selenium 
concentration in blood, tissues, and excreta.   
Plasma Se 
Protein bound Se is associated to α and β - globulins of lipoproteins. Plasma and serum 
Se concentrations are comparable and both reflect short term changes in Se intake, mainly of 
SeMet compared to inorganic forms of Se [119]. SeMet is not subject to homeostatic control as 
this form of Se incorporates into tissue proteins in place of methionine [120]. Plasma Se values 
less than 0.1 µmol/L are associated with depletion and with clinical features  of deficiency [121]. 
There are no universally agreed upon cut-off values for plasma Se [122]. Cut-off points suggested 
by Thomson are only for assessment of the adequacy of Se [123]. Plasma or serum Se are 
measured more accurately using inductively coupled plasma mass spectrometry (ICP-MS) [122]. 
Plasma Se is said to be affected by Se intake, age, puberty, pregnancy and lactation, prematurity, 
smoking and chronic diseases in humans [122]. Due consideration must be given to these factors 
while interpreting results. 
Whole Blood Se 
Whole blood Se is stable and is used as an index of long term Se intake [122]. The whole 
blood Se changes after a period of depletion (months), which makes the relationship of current Se 
intake with whole blood concentration somewhat difficult to associate [122]. As a result, criteria 
for interpretation of the values of whole blood Se have not yet been established. Whole blood Se 
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could also be assessed using AAS and ICP-MS, though the analysis is said to be difficult. Factors 
affecting plasma Se  affect concentration of Se in whole blood as well [122]. 
Erythrocyte and Platelet Se 
Erythrocyte Se is mostly associated with the hemoglobin, while only 15% is associated 
with its glutathione peroxidase. This too reflects long term Se status. For people consuming stable 
intakes of Se, positive correlation was seen between erythrocytes, plasma and dietary intake 
[124]. Erythrocyte Se is lower in disease conditions that affect absorption of Se, and it responds 
slowly to Se supplementation compared to plasma Se. The longer period required for the 
synthesis of the erythrocyte and the limited transferability of hemoglobin-bound Se contributed to 
slow response of erythrocytes to Se supplementation [125]. The type of Se used for 
supplementation determines the rate of response by erythrocytes. The erythrocyte response to 
supplementation with inorganic Se is slower than with SeMet, even though SeMet is not subject 
to homeostatic regulation [126]. Determination of erythrocyte Se is not highly recommended due 
to problems with measurements. Information on factors affecting erythrocyte Se concentration is 
lacking but associations exist between chronic diseases affecting Se absorption, long term low Se 
intake, genetic diseases such as sickle cell anemia and Down’s syndrome [127]. 
Urinary Se 
Se excretion in urine helps to regulate homeostasis of Se in the body and it is  the major 
excretory pathway for Se (50 - 60%), while the remainder gets excreted via feces [128]. Urinary 
excretion correlates well with dietary intake and plasma Se such that dietary Se intake can be 
roughly estimated to equal twice as much as urinary Se [129]. Urinary Se excretion is lower in 
females, pregnant women and aged people [122] and reduction of Se in the aged population is 
associated with reduction in muscle mass [130]. Urinary Se is used as an index of toxicity and the 
allowable maximum  concentration is at 1.3 µmol/L [131]. Fasting urine samples are preferred for 
measurement of urinary Se at the population level [122]. A fluorometric method is commonly 
used to measure urinary Se but the AAS method can also be used [122]. 
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Gpx 
Glutathione peroxidase activity in cells and plasma is used for the assessment of long and 
short-term selenium deficiency, respectively [30, 132].  When Se intake is below threshold (1.15 
µmol/L), erythrocyte Gpx1 activity is used to assess Se status and it correlates with whole blood 
or erythrocyte Se level [133].  The correlation no longer exists when Se intake is beyond the 
threshold value  making it a difficult indicator of Se status [134].  Gpx1 activity in platelets is 
also a sensitive indicator as platelets contain significantly higher concentration of Se than any 
other tissues and have a high turnover.  On the other hand, platelet separation is difficult [134].  
Gpx3 is measured more accurately than other glutathione peroxidases and it contains 12% of the 
Se in plasma [135].  A strong correlation has been identified between plasma Se and Gpx3 
activity [126], and  plasma Se and Gpx3 are said to be good measures of Se status [120].  Plasma 
Gpx3 activity increases following supplementation and this is not dependent on the type of Se 
used for supplementation [122].  Gpx3 is also used in population studies where Se status is low 
[124].  Gpx3 is more stable at -80°C than Gpx1 activity.  Enzyme-linked immunosorbant assay 
(ELISA) kits are also used [122]. 
Plasma selenoprotein P 
Selenoprotein P is said to be more sensitive to Se deficiency than glutathione peroxidase 
activity [133].  Response to Se supplementation by selenoprotein P is higher than Gpx3 [136] and 
selenoprotein P and plasma Se correlate positively with Se status  [122].  Optimal level for 
plasma selenoprotein P has yet to be defined [122].  Selenoprotein P could be measured by 
competitive radioimmunoassay using 75Se labeled human selenoprotein P [135].  
Molecular biomarkers 
 In rodents mRNA levels used to determine Se requirements have revealed a hierarchy in 
the transcriptome level of selenoprotein expression [137].  Gpx1 is less labeled than other 
selenoproteins in Se deficiency [137], while Sepp1 (gene that encodes selenoprotein P) and DIOl 
mRNA levels decrease less than Gpx1 mRNA levels [138].  Sunde and colleagues reported that 
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blood Gpx1 mRNA can be used as a molecular biomarker to verify dietary Se requirements in 
rats [139].  Barnes and co-workers characterized the Se regulation of rat molecular biomarkers in 
liver, kidney, and muscle in Se depleted (<0.01 µg Se/g diet) male weanling rats and rats with 
graded levels of Se (0 – 0.8 µg Se/g diet).  Most selenoprotein mRNA was found not to be 
significantly regulated by Se status, with the exception of selenophosphate sythetase-2, which 
was up-regulated in Se deficiency.  No biomarkers for Se status determination were characterized 
for high (> 0.8 µg Se/g diet) Se intake [140].   
There is inadequate data on the biomarkers of Se status in humans [123]. Sunde and 
colleagues conducted a longitudinal study in the U.K. measuring the efficacy of molecular 
biology markers for assessing Se status in humans [141].  In addition to biochemical markers like 
levels of plasma Se, selenoprotein mRNA levels from ~40 participants with an average plasma Se 
concentration of 1.13 ± 0.16 µmol/L (35.13 ± 5.44 mg/L) were taken as molecular biomarkers.  
No significant change was seen over time in mRNA levels and levels did not correlate with 
plasma Se, indicating that the subjects were on the plateau of the Se response curves.  Although 
the molecular biomarkers were readily detectable, they did not distinguish differences in Se 
levels, particularily when plasma levels were this low [141].  
Hair and Toe Nail 
Hair and toenails can be used as indicators of short-term and long-term selenium intake, 
respectively [122].  There are 4 main analytical methods used to assess selenium status [142-145].  
Selenium status determination through fluorometry requires very precise, minute measurements 
of Se with the main risk being Se loss during dissolution of a given sample [142].  Neutron 
activation analysis is also used for Se measurement in biological samples, and is a relatively 
faster method.  However, it requires the use of research reactors [143].  Routine analysis is more 
commonly performed by atomic spectroscopy using either hydride generation [144] or graphite 
furnace [146].  Inductively coupled plasma-mass spectroscopy can also be used to measure 
selenium in combination with analysis of other elements [145]. 
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Multiple Indices 
For individuals with low Se status, the measurement of total Se and Gpx3 in plasma is 
recommended [122]. For those having adequate Se status, Se status could be assessed by  total Se 
in plasma and erythrocytes as a marker of current and longer term status respectively [122]. When 
blood collection is limiting, analysis of toenail Se is recommended as a marker of long term Se 
status. When Se status is studied as a risk factor  for disease, interaction of Se with other 
antioxidant nutrients, polyunsaturated fats, heavy metals and iodine status must be investigated to 
rule out any confounding effects of these nutrients [122]. 
Selenium Deficiency 
Manifestations of Se deficiency are species specific. In mice, deficiency causes 
degeneration of muscle and organs such as liver and pancreas and reproductive failure in male 
rodents due to defects in sperm production [147]. Rats fed on a diet that was deficient in Se, 
vitamin E and sulfur amino acids developed liver necrosis, which caused reproductive failure and 
death within three to four weeks.  Diets deficient in Se but not in vitamin E and sulfur amino 
acids fed to rats and chickens showed that Se was still an essential nutrient [148].  Se deficiency 
in mice results in multiple necrotic degeneration of skeletal muscle, heart, kidney, liver, and 
pancreas and reproductive failure.  [148].  Knockout mice models have been used to show Se as 
key in neurological function and gastrointestinal disease [100, 149].   
Various species of food animals have different responses to chronic Se deficiencies [6].  
Mulberry heart, a cardiac condition, is present in swine low on Se [67].  Lambs present with 
muscular dystrophy known as white muscle disease.  Turkeys develop gizzard myopathy and 
cattle develop myopathy of skeletal and heart muscle [67].  In cattle, Se deficiency resulted in 
muscle myopathy and reproductive system problems, manifested as reproductive failure in bulls 
and retention of placenta in cows [147]. Chickens with severe Se deficiency manifested with 
symptoms related to exudative diathesis secondary to degeneration of capillary beds [147] . The 
reasons for these species specific manifestations of Se deficiency are not clear. 
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In humans, selenium deficiency is associated with Keshan disease, which is an endemic 
juvenile cardiomyopathy due to low Se intake [150].  It is reported mainly in areas of China and 
Eastern Siberia where low Se content in the soil is common (mean Se content 0.125 µg/g) [151].  
A comprehensive supplementation of Se in the 1970s was used to combat Keshan disease in the 
peasant population of certain hilly and mountainous regions in China with soil low in Se [66].  
Several studies contributed to the decisions for the governmental supplementation program [152].  
More recently, selenium supplementation for children in Kashin Beck Disease-affected 
areas of China has been investigated by Chinese scientists [153].  Bai and colleagues orally 
supplemented children ages 3-13 years with sodium selenite in Jingcuan County of the Ganshu 
Province for 2 years.  In children, selenium content increased from 56.5 ng/g to 251.7 ng/g and 
metaphyseal damage detected by finger X-ray decreased from 79.2% to 34.4%.  In children 
without supplementation, however, the researchers saw an increase in the detected metaphyseal 
damage of finger X-ray from 57.6% to 65.5% showing that selenium supplementation promoted 
lesion repair [154].  In Guide County of the Qinghai Province, Li and colleagues administered 
three different types of oral selenium supplementation to children.  The supplementation period 
lasted for a year and showed a therapeutic effect on metaphyseal joints.  Additional data on 
participants were not available [155].   
A report from New Zealand of patients given total parenteral nutrition (TPN) without Se 
supplementation showed a tendency towards Se deficiency [156].  After surgery and TPN, 
patients exhibited symptoms including dry flaky skin, bilateral muscular myalgia and pain with a 
great drop of plasma Se from 25 µg/L to 9 µg/L after surgery and TPN [156].   
Selenium and iodine deficiency interact and lead to the development of endemic 
myxedematous cretinism manifested by goiter and lowered intelligence and neurological 
disorders [147]. Se supplementation alone without a concurrent iodine supplementation leads to 
aggravation of the condition due to activation of deiodinases, which increased synthesis of T3 
exacerbating iodine deficiency  [157].   
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Selenium Toxicity 
Acute and chronic selenium toxicity were first reportedly seen in livestock due to high 
soil levels resulting in the accumulation of selenium in plants [158].  Inorganic selenium and 
selenoaminoacids have increased bioavailability and could be toxic, if consumed in excess, as 
opposed to methylated forms (trimethylselenonium chloride, dimethylselenide) which are less 
toxic.  Hydrogen selenide is in comparison the most toxic form.  The biomechanical mechanism 
underlying selenium toxicity is not known.  The human body lacks homeostatic mechanisms to 
control or reduce Se absorption even under chronic toxic intake [36].  Safer and colleagues 
reported selenite inactivating eukaryotic initiation factor 2-α [159] but more detail is not well 
known.  To examine the mechanism of toxicity in mice, Hasegawa and colleagues investigated 
the liver of Imprint Control Region (ICR) male mice treated with selenocystine [160].   
In humans, modest intakes of selenium (<800 µg Se/d) are not evidenced to be 
toxic[161].   A study in South Dakota and Wyoming on Se in the water supply showed no signs 
of selenium toxicity in 142 subjects who consumed as much as 724 µg Se/d [162].  Increased 
levels (50x higher than the standard 10 µg/L) of inorganic Se in well water resulted in increased 
Se in urine in humans but not in blood [162].  Blood concentration in this study did not reflect the 
exposure to increased Se intake [162].  
More common than acute selenotoxicity is human chronic selenium toxicity which results 
in hair loss and brittle nails [163].  Exacerbated selenosis presents with skin lesions, 
gastrointestinal issues, nervous system disturbances and mottling of the teeth [161].  Abnormal 
endocrine function, reduced synthesis of thyroid and growth hormones, and reduced metabolism 
of insulin-like growth factor have also been reported.  Effects on the immune system have also 
been documented with low natural killer cell production and hepatotoxicity [164].  Excess Se has 
also been postulated to inhibit protein synthesis and increase the risk of cancer by catalyzing 
hydrosulfide oxidation [164].  In China, nail morphology was used as an endpoint to calculate the 
no-observed adverse-effect level (NOAEL) for selenium [165].  The participants with nail 
28 
 
problems exhibited lower glutathione concentrations and slightly longer prothrombin times [165].  
Yang et al calculated 853 µg Se/d as the NOAEL value [165] and this was used to set the UL of 
Se at 400 µg Se/d [163].   
Fatal toxicity from supplements has also been reported.  Helzlouer and colleagues 
reported 13 people who took dietary selenium with 27.3 mg Se/tablet, which was 182 times 
higher than indicated on the label [166].   
McConnell and Portman reported in 1952 the median lethal dose for mice at 1.3 g of Se 
as dimethyl selenide per kg of body weight (1.8 g of dimethyl selenide total injected through 
intraperitoneal injection), and 1.6 g of Se per kg of body weight (2.2 g dimehtyl selenide) for rats 
[167].  In rats, 0.1 µg Se/g diet is the minimum dietary requirement, while intake over 2 µg Se/g 
diet produces toxicity [67] resulting in a 20 fold factor difference between the requirement and 
the onset of toxicity.  Wilber reported the toxicity in rats of different selenium compounds 
injected via the intraperitoneal gland, and found sodium selenate to be 5.5 – 5.8 mg/kg body 
weight [168].  Raines and Sunde measured Se regulation of the liver transcriptome (all RNA in 
the cell) in mice and rats with three microarray experiments.  The weanling mice and rats were 
fed Se-deficient diets supplemented with up to 5 µg Se/g diet.  They found no toxicity effect in 
mice at 0.2 µg Se/g diet and in rats at 2.0 µg Se/g diet.  Rats fed 5 µg Se/g diet showed 23% 
reduced growth when compared to Se-adequate rats, and significantly altered expression of over 
1000 liver transcripts.  High but non-toxic Se intake for both mice and rats (less than 2 µg Se/g 
diet) had fewer than 10 transcripts altered [169].   
Effects of Selenium on Bone 
Antioxidant protection can be observed from physiological doses of selenium.  As an 
essential cofactor of glutathione peroxidase, selenium is important in the reduction of hydrogen 
peroxide: a product of oxidized species [170].  Dreher and colleagues showed antioxidative 
defense for human fetal osteoblasts that was mediated by expressed glutathione peroxidase.  Their 
evidence suggested that glutathione peroxidase expression is essential for osteoblast function and 
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could be involved in metabolic bone diseases [171].  A model of heparin-induced osteoporosis in 
New Zealand white rabbits showed sodium selenite to restore structural alterations in femur when 
taken in combination with vitamin E and C [172].  Rats supplemented with selenium (0.15 mg/kg 
diet) showed less necrosis in the chondrocytes of the growth plates of tibia when compared to rats 
fed a diet from Kashin-Beck disease endemic areas.  They also showed better bone volume/tissue 
volume ratio (BV/TV), trabecular thickness, and trabecular number, and reduced trabecular 
separation [173].   
Impact of Selenium Deficiency on Bone Health 
Selenium deficiency is associated with Kashin-Beck disease, a severe type of 
osteoarthritis that affects the bone and joints [174].  It is a degenerative, disabling endemic 
osteoarticular condition that affects the bone and joints of its sufferers, with a typical onset in the 
first or second decade of life.   
Kashin-Beck disease (KBD) was first identified in 1849 by a Russian doctor, Nikolai 
Ivanonvich Kashin, but its cause is still unknown.  In Tibet, the risk factors seem to include 
selenium deficiency in the soil [10], fungal contamination of barley (the staple grain) [175], 
organic matter (fluvic acid) in the water [10], and iodine deficiency [176].  Kashin-Beck disease 
has been reported in certain areas of Tibet, northern China, Mongolia, Siberia, and North Korea 
[10, 177].  Thirty million people are reported to live in areas of China where the disease is 
endemic, and about 2-3 million of this population are estimated to be affected [10].   
Early symptoms of KBD in pre-adolescents and adolescents include stiffness, swelling, 
and pain in the interphalangeal joints of the finger; symptoms that are reported as been reversible 
[9].  Disease progression into the third decade of life presents with generalized osteoarthritis in 
the elbows, knees, and ankles, and with joint locking [9, 178].  Impaired bone development as a 
result of degeneration and necrosis of the bone’s epiphyseal growth plate has been suggested by 
Ge and Yang [179].  While selenium deficiency is accepted as a cause of the disease, all 
selenium-deficient areas do not exhibit the disease, implicating other factors as necessary for full 
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development of true Kashin-Beck disease.  Kashin-Beck disease has been suggested by Suetens 
and co-workers to result from oxidative damage to cartilage and bone cells when associated 
which decreased antioxidant defense [180]. 
Reactive oxygen species are produced during the process of bone resorption.  Active 
osteoclasts produce superoxide, NO·, and H2O2.  H2O2 is believed to be the principal stimulator of 
bone resorption.  Modulation of H2O2 may be an important way by which bone metabolism is 
regulated [181].  It has been found that NO· is produced by both the osteoblast and osteoclast and 
that it has major effects in producing osteoclast detachment and exerting a toxic inhibition of 
bone resorption [182].  Key and colleagues conducted a study that suggested that superoxide 
generated at the osteoclast-bone interface is involved in bone matrix degradation [183].  The 
researchers localized superoxide formed along the osteoclast-bone interface by demonstrating the 
electron-dense deformazan granules between the osteoclastic membrane and the bone surface.  
The formation of this reaction product was inhibited by a superoxide scavenger, the deferoxamine 
mesylate-manganese complex, confirming the specificity of the reaction product.  The scavenger 
also inhibited bone resorption.  High concentrations of superoxide generated in vitro at neutral pH 
degraded osteocalcin into numerous peptide fragments, demonstrating the ability of superoxide to 
break peptide bonds [183].    
 The deficiency of selenium played a role in the etiology of Kashin-Beck disease in 
selenium-deficient male Wistar rats [184].   The rats were fed the Se depleted diets for 3 – 11 
months, after which they were killed.  Their articular cartilages were studied both with light and 
electron microscope but no clear changes in the articular chondrocytes were observed from light 
microscopy.  The electron microscope, however, showed degeneration in the deeper layers of the 
chondrocytes.  Sasaki and colleagues also measured the bone mineral density (BMD) of femur 
using the microdensitometry method and ash weight.  Rats in the Se-deficient group sacrificed 
from the 5th month onward had lower BMD (ash weight).  Serum Se concentrations, alkaline 
phosphatase activity, and urine Se concentrations were decreased as well.  [184].  Mice fed a Se 
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deficient diet and supplemented with fulvic acid had decreased cartilage in the knee joints and 
developed fibrocartilage at the articular surface, similar to early stages of osteoarthritis [185].  
There was also underdevelopment of the articular space and meniscus, while the subchondral 
bone was poorly formed, and early differentiation was not seen during endochondral ossification 
[185].  Similarly, Yao and colleagues investigated the effects of supplemental selenium and 
selenium with iodine on bone and growth plate cartilage histology on 96 Wistar rats of both sexes 
that were randomly given either a control diet, a depleted diet, a selenium supplemented diet, or a 
diet with both iodine and selenium [153].  After 4, 8, and 12 weeks, rats were randomly sacrificed 
and the left knee including the distal femur and the proximal tibia was harvested and fixed in 4% 
(w/v) formaldehyde.  The static parameters analyzed consisted of the bone volume/tissue volume 
ratio (BV/TV), the trabecular thickness (TbTh), the trabecular separation (TbSp), and the 
trabecular number (TbN).  The rats on the depleted diet had comparatively reduced BV/TV, 
TbTh, and TbN while TbSp was increased [153]. 
Selenium deficient and fulvic acid supplemented mice, considered by Yang and 
colleagues [161] to be an animal model of Kashin Beck-disease, had irregular bone formation and 
substantial reduction in the number of lysine residues in type I collagen from bone and type II 
collagen from cartilage.  A lower melting point of type I collagen from bone, and lower breaking 
force of bone were also found in the animals.  In a study aiming to understand the role of 
selenium deficiency in the etiology of Kashin-Beck disease, Sasaki and colleagues [159] 
observed decreased femur ash weight, and a decrease in the sulfotranferase activity (involved in 
glucosaminoglycan synthesis) in 3 to 11 month selenium-deficient rats. 
Suetens and colleagues [155] also suggested a second mechanism whereby normal 
stimulation of bone remodeling by thyroid hormones may be blocked by certain mycotoxins in 
the fungal contaminated grain.  Chasseur and colleagues [149] did not observe a decrease in the 
prevalence of Kashin-Beck disease by iodine supplementation when a fungal species (Alternaria 
sp.) was present, and thus suggested a competitive binding of a mycotoxin to a thyroid hormone 
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receptor in bone cells.  Fulvic acid, an environmental contaminant involved in the etiology of 
Kashin-Beck disease, has been shown to covalently bind with iodine [162], suggesting that fluvic 
acid may interfere with iodine bioavailability.   
Ren and colleagues studied the role of combined selenium and iodine deficiency in bone 
development as a possible experimental model for Kashin-Beck osteoarthropathy in 48 Sprague-
Dawley rats and showed that combined selenium and iodine deficiency impaired the growth of 
bone and cartilage [163].  The rats were randomly divided into four different diet groups:  
Selenium and iodine deficient, selenium sufficient and iodine deficient, iodine sufficient and 
selenium deficient, and selenium and iodine sufficient diets.  They found that mean tibial length 
of rats fed the depleted diet was significantly shorter.  The group that consumed the selenium 
sufficient and iodine deficient diet had smaller proliferative zones and thinner growth plate 
cartilage [163].   
Role of Pro-Inflammatory Cytokines and Free Radicals in Bone Loss 
Normal growth and development in young growing mammals (humans and rodents) 
depends on many factors including growth hormone (GH), thyroid hormones and nutritional 
status.  The growth promoting effect of GH is believed to be mediated in part by insulin-like 
growth factor-1 (IGF-1) [164].  Growth hormone causes the liver (and to a lesser extent other 
tissues) to produce several small peptides called somatomedins (at least four somatomedins have 
been isolated), that in turn have potent effects of increasing all aspects of bone growth [165].  The 
most important of these is somatomedin C, also called IGF-1, which in turn regulates GH 
secretion through a feedback stimulation of somatostatin [164].  Both GH and IGF-1 influence 
bone growth and increase bone mineral content and bone mineral density [166].  The 
bioavailability and bioactivity of IGF-1 are modulated by IGF-binding protein-3 (IGFBP-3), a 
GH dependent glycoprotein and the main carrier for IGF-1 in blood [164]. 
Yanavski and coworkers [166] investigated bone status and the levels of IGF-1 and IGF 
binding protein in white and African American girls and found BMC, BMD and free IGF-1 to be 
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higher in African American than white American girls, while IGF-binding protein-3 was similar 
or lower in African American girls.  In the study, free IGF-1 was positively correlated with BMC 
and BMD in both groups.   
A study by Basu and colleagues examined the role of free radicals in bone resorption by 
looking at the effect of oxidative stress on bone mineral density (BMD) in 48 women and 53 men 
from a population-based study.  The specific biomarkers they examined included 8-iso-PGF2  (a 
major F2-isoprostane and a biomarker of oxidative stress) and a control, 15-keto-dihydro-PGF2  
(a biomarker of inflammatory response) through analysis of urine samples and quantitative 
ultrasound (QUS) measurements.  Through multivariate linear regression analyses, 8-iso-PGF2  
were negatively associated with bone BMD and QUS, while no association was found for 15-
keto-dihydro-PGF2 .  Their findings established a biochemical link between increased oxidative 
stress and reduced bone density [167].   
Bone turnover is regulated by a balance between osteoblast (bone-forming) activity and 
osteoclast (bone-resporption) activity [5, 156] .  Smith and colleagues reported the use of 90-day 
time-release lipopolysaccharide (LPS) pellets to study effects of inflammation on bone [168].  To 
develop an in vivo model of bone loss induced by chronic systemic inflammation, twenty-four 3-
month-old male Sprague-Dawley rats (Harlan, Indianapolis, IN) were randomly assigned to one 
of three groups:  Low dose LPS (3.3 µg/day), high dose LPS (33.3 µg/day), or placebo.   The rats 
were anesthetized with an intramuscular injection of a ketamine/acepromazine/atropine cocktail 
(35 mg, 1.5 mg, and 0.04 mg per kg body weight, respectively) for implantation of the pellet.  
Tail blood samples were collected at one month, two month, and three month points of the study 
period for a neutrophil count.  At the end of the study, day 90, rats were anesthetized, DEXA 
scanned, and bled via cardiac puncture.  To assess the alterations in local regulators of bone 
metabolism and inflammation-related proteins in the proximal metaphysis of the tibia, 
cyclooxygenase (COX)-2, tumor necrosis factor (TNF)-α, and interleukin (IL)-1β expression 
were evaluated by immunohistochemistry.  Neutrophil counts were elevated (P< 0.05) in the low 
34 
 
(971 x 103 cells/mL) and high  (1049 x 103 cells/mL) dose LPS groups at 30 days compared to 
placebo (405 x 103 cells/mL).    Neutrophils remained elevated in the High dose group at 60 (912 
x 103 cells/mL) days and at the end of the study (860 x 103 cells/mL) indicating that inflammation 
was still present and the animals had not yet developed a tolerance at the tissue level.  
Immunohistochemistry revealed LPS induced a dose-dependent increase in the expression of 
COX-2 – the rate limiting enzyme in PGE2 production – in the proximal tibial growth plate region 
and metaphysis.  An increase was also seen in TNF-α and IL-1β (P<0.05) in the tibial metaphysis.  
In the epiphyseal region of the proximal tibia, the only inflammatory mediator to have this 
behavior was COX-2.  TNF-α and IL-1β showed increase in this region of the tibia only in the 
high dose group.   In general, osteoclast and monocyte-like cells had stronger intensity of staining 
for IL-1β and TNF-α in the proximal tibia metaphysis than in the epiphyseal plate.  Bone loss was 
confirmed through DEXA and µCT analysis of excised femur and tibia [168].   
Indicators of Bone Quality 
The quality of bone is defined through measures of bone strength such as material 
properties (collagen and mineral), which are affected by turnover and structural properties 
(geometry and microarchitecture) [169].  Bone quality may be determined by several factors, 
including its properties that affect its strength.  The geometry of bone consists of the size and 
shape of bone.  The size of bone is a determinant of bone strength.  Reduced bone mineral content 
and a smaller vertebral bone were seen in women with fractures of the spine [170].  Silva and 
Gibson developed a 2-dimensional model of human vertebral trabecular bone from four women 
(ages 47, 55, 85, and 86 years) and investigated its mechanical behavior using finite element 
analysis [170].  The structural arrangement of bone (microarchitecture) is also strongly related to 
bone strength [171].  Turan and colleagues studied the microarchitecture in rats fed diets with 
graded quantities of selenium and vitamin E.  The stiffness (modulus of elasticity) of bones 
(femur and tibia) was measured by a tensile test, and biomechanical strength of both the deficient 
and excess groups were decreased when compared to control [171].   
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Collagen content and structure also affect bone quality.  There is a reduced concentration 
of cross-links in bones from patients with osteoporosis [169].  Collagen has smaller influence on 
the stiffness of bone, but improves bone toughness through intramolecular cross-links [172].  
Collagen fiber orientation explained 71% of variation in bone tensile strength in a linear 
regression analysis [173].  Bone is formed by the production of a protein framework that hardens 
when calcium and phosphorus are deposited on it.  Bone strength partly depends on this mineral 
deposition [173].  Apart from bone mineral content, the perfection and the maturity of mineral 
crystals are also important determinants of bone strength [173]. 
Bone Mineral Density 
Bone mineral density refers to the amount of minerals in a three-dimensional volume of 
bone.  However, bone mineral density is also estimated by dual energy X-ray absorptiometry 
(DEXA) based on a two-dimensional area.  There is a strong correlation between fracture risk and 
low bone mass.  The WHO has developed diagnostic categories that compare a person’s bone 
density with the peak value for a healthy young adult using a T-score [174].  A normal bone is 
indicated when bone mineral density or bone mineral content is within 1 standard deviation (SD) 
(+1 SD or -1 SD) of the young adult mean value.  A low bone density (osteopenia) is indicated by 
a bone mineral density or bone mineral content of 1 to 2.5 SD below the young adult mean (-1 to 
-2.5 SD).  Osteoporosis is defined by a bone density or bone mineral content of 2.5 SD or more 
below the young adult mean (>-2.5 SD).  Severe osteoporosis is said to exist when bone mineral 
density or bone mineral content is more than 2.5 SD below the young adult mean and there have 
been one or more fractures due to osteoporosis [174].   
Bone Microarchitecture 
Bone mass is not the only property that affects bone strength.  The microarchitecture of 
bone is also an important factor in strength, and is considered in measuring bone mechanical 
properties.  Bone microarchitectural parameters of trabecular bone like trabecular number (TbN), 
trabecular thickness (TbTh), trabecular separation (TbSp), connectivity density, and parameters 
36 
 
of cortical bone such as width and porosity indicate bone fragility independent of bone density 
[175].  An aged model of human vertebral trabecular bone was developed by Silva and Gibson by 
concurrently reducing the trabecular thickness and trabecular number of a young model with 
intact values.  Trabecular number and thickness decrease in aging.  Increase of trabecular 
thickness alone in the model saw bone mass rebounding as strength increased by 60%, but this 
was only 37% of its original value.  Therefore, increase of trabecular number seems to be 
essential for full recovery of bone loss [170].   
The structural model index (SMI) is a 3-D bone structural parameter that quantifies the 
plate versus rod characteristics of trabecular bone [176, 177].  An SMI of zero (0) pertains to a 
purely plate-shaped bone, and a value of 3 indicates a purely cylindrical rod-like structure, and 
values between designate mixtures of plate and rod forms [177].  Human tibial cancellous bone 
changes with aging from plate-like to rod-like, indicating a deterioration of the structure of bone 
with aging [176].   
Microarchitectural deterioration such as decreased trabecular connectivity has been 
related to increased possibility of fracture and one of the positive effects of parathyroid hormone 
(PTH) on bone is the restoration of moderate lost trabecular connectivity [178].  Even though 
connectivity is believed to be important in the biomechanics of bone in osteoporosis [178], there 
is not much evidence to support this hypothesis  in healthy bone.  Kabel and coworkers observed 
an inverse association of connectivity with bone stiffness [179].  Connectivity seems to be 
inversely associated with elastic  properties of cancellous bone of people with no known bone 
disorders.   
Degree of anisotropy (DA) refers to the extent to which a material has different properties 
in different directions [180, 181].  Poor bones seem to have higher DA values.  An analysis of 
porous hydroxyapatites with an anisotropic characteristic (higher DA) intended for the bone-graft 
market found the specimens to possess lower compressive moduli than isotropic specimens with 
the same apparent densities [182].  Similarily, Chappard and colleagues [181] found higher DA 
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values in the bone of subjects with vertebral fracture than in control subjects.  Furthermore, an 
improvement in the structural properties of the vertebra (L1 and L2) of dogs following alendronate 
treatment was accompanied by a decreased degree of anisotropy in the bone specimens [183]. 
Bone Biomechanical Properties 
Biomechanical properties of bone are those properties of bone that are associated with 
elastic and inelastic reactions when a force is applied.  They also involve the relationship between 
stress and strain [184].  Biomechanical properties range from elastic abilities to stress responses 
of bone, and include stiffness, hardness, strain, fatigue life (fracture of bone under repetitive 
stress), and strength [185].  Bone strength depends on bone matrix volume, bone 
microarchitecture and the degree of mineralization of bone [186].  The more cancellous bone is 
mineralized, the higher its stiffness.  Young human bone is less mineralized than mature bone 
[186].  Ciarelli and colleagues suggest that both low and high mineralization may be deterimental 
to bone mechanical properties, with low mineralization level causing reduced stiffness and 
strength and high mineralization leading to reduced fracture toughness due to increased 
brittleness [187].   
Bone mechanical properties can be determined using three or four point bending 
techniques and fatigue tests for long bones [180, 185, 188].  The compressive tests are more 
appropriate for small and cubic samples or trabecular bone [186]. 
There is not much information about the effects of iodine and selenium on the 
biomechanical properties of bone in growing individuals.  However, retarded growth and lower 
breaking force of the tibia have been observed in selenium-depleted mice compared to controls 
[161].  Growth retardation and osteopenia were seen in second generation selenium-deficient 
male rats [189].  Methamizol-induced hypothyroidism during postnatal development leads to 
decreased bone length and biomechanical competence (measured as Vickers microhardness) of 
the femora and humeri in birds [190].   
Biomarkers of Bone Metabolism 
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 Bone density determination is valuable for evaluation of patients at risk for osteoporosis, 
but it does not give any information about the rate of bone turnover, therefore, supplementing 
bone density information with measurement of markers of bone turnover may enhance the 
prediction of fracture risk.  Bone markers indirectly measure bone cell activities [177].  
Biochemical markers of bone metabolism are byproducts that are released into the blood stream 
and urine during the process of bone remodeling, which involves bone resorption and bone 
formation [191].   
 Serum and urine tests can detect these markers and provide information about the rate of 
bone resorption and formation.  Bone formation can be evaluated using serum non-specific 
alkaline phosphatase (ALP), bone-specific alkaline phosphatase (B-ALP), osteocalcin, 
carboxyterminal propeptide of type I collagen (PICP), and aminoterminal propeptide of type I 
collagen  (PINP) [191].  Indicators of bone resorption such as cross-linked C-telopeptide of type I 
collage, tartrate resistant acid phosphatase (TRAP), N-telopeptide of collagen cross-links (NTx), 
and C-telopeptide of collagen cross-links (CTx) can be determined in serum.  Other bone 
resorption markers such as hydroxyproline, free and total pyridinoline, free and total 
deoxipyridinoline as well as NTx and CTx can be assessed in urine [191].   
 Bone specific alkaline phosphatase is an osteoblast product that is believed to be an 
essential enzyme for bone mineralization [191].  Both bone specific and tissue non-specific 
alkaline phosphatase can promote mineralization by hydrolyzing a variety of phosphate 
compounds to make inorganic phosphate available for bone mineralization [192].  It has been 
suggested that alkaline phosphatase may destroy inhibitors of mineral crystal growth and behave 
like a calcium binding protein [193].   
 Osteocalcin (bone gla-protein) is a peptide synthesized and secreted by osteoblasts during 
bone formation.  It is mostly incorporated into bone matrix with some escaping into the blood; 
therefore, osteocalcin is accepted as a marker of bone formation.  However, osteocalcin is also 
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released from bone to the circulation during bone resorption.  Therefore, osteocalcin is more a 
marker of bone turnover than of bone formation [191]. 
 Aminoterminal and carboxyterminal propeptide of type I collagen direct the assembly of 
the collagen triple helix and are separated from the newly formed collagen molecules and 
released into circulation [191].  Therefore, their concentration in serum may be an index of bone 
formation.  However, these byproducts of collagen synthases are also produced by other type I 
collagen and are less useful than alkaline phosphatase (ALP) and osteocalcin (OC) as indicators 
of bone formation [191].   
 TRAP (tartrate resistant acid phosphatase, also known as type-5 acid phosphatase) is an 
iron-containing protein produced in different tissues with acid phosphatase activity and is one of 
the most abundant enzyme in osteoclasts [194].  Serum TRAP is used as a biochemical marker of 
osteoclastic activity and bone resorption [195].  However, it lacks specificity because other cells 
that are not related to bone such as erythrocytes and platelets also release TRAP into serum [195].   
 NTx and CTx are degradation products of type I collagen, mainly produced by cathepsin 
K. Pyridinoline, deoxypyridinoline, and cross-linked C-telopeptide of type I collagen (ICTP) are 
also degradation products produced by matrix metalloproteases [196].  Pyridinoline and 
deoxypyridinoline are the two cross-links present in the mature form of type I collagen.  Urine 
levels of pyridinoline and deoxypyridinoline correlate with the breakdown of collagen released 
from bone matrix by the osteoclasts [197].  This cross-linking structure, which is unique to 
collagen and elastin molecules, creates bonds between polypepetide chains in collagen fibrils to 
enhance stability.  Pyridinoline and deoxypyridinoline cross-links can be excreted free or still 
bound to the peptide chains and either form can be measured.  Deoxpyridinoline is the more 
abundant cross-link in bone collagen and is generally the one measured [197]. 
Studies on the Effects of Selenium on Bone 
 Selenium is required for T3 synthesis and thyroid hormone homeostasis [198].  Therefore 
it may indirectly protect bone through thyroid hormones.  Physiological doses of selenium may 
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also directly protect bone through its antioxidative properties.  Selenium is an essential 
component of the enzyme glutathione peroxidase as well as thioredoxin reductases as the active 
center of which selenium catalyzes reduction of hydroperoxides produced from oxidized species 
such as superoxide and lipoperoxides [143].  Thus, it may protect bone and cartilage cells against 
oxidative damage [144].  Dreher and colleagues [144] demonstrated a selenite-dependent Gpx 
mediated antioxidative defense of fetal human osteoblasts against hydrogen peroxide and reactive 
oxygen species.  In the study it was shown that osteoblasts express an antioxidative system to 
protect themselves against H2O2 after bone resorption is mediated by osteoclasts.  Therefore, lack 
of Gpx may lead to impaired osteoblast function and could be involved in metabolic bone disease.     
Selenium in Cell Culture Studies 
Using a cell culture model, Lean and colleagues suggest that estrogen provides a 
protective effect for bone through the lowering of reactive oxygen species (ROS) concentrations 
via better antioxidant activity.  High concentrations of ROS not only damage cell constituents, but 
could also affect signaling proteins like TNF-α and NF-kβ, which, at appropriate levels, are 
essential for osteoclast development. Cytokines such as IL-1 upregulate their own activity by 
inducing the production of oxidants that may inhibit cytosolic enzymes.  Selenium dependent 
glutathione peroxidases and thioredoxin reductases help keep cytosolic enzymes in their reduced 
form, therefore adequate selenium nutrition may protect bone by down-regulating cytokine 
signaling [199]. 
Selenium in Epidemiological Studies 
An epidemiological study on patients with rheumatoid arthritis (RA) showed healthy 
controls having significantly (<0.001) higher plasma selenium concentrations than the patients 
[200].  Likewise, Kamanli and colleagues found lower concentrations of plasma Gpx, catalase, 
glutathione, β-carotene, and vitamin E in patients with RA as compared with the controls,  In the 
same study, significantly higher concentrations of C-reactive protein, lipid peroxidation markers, 
and rheumatoid factor were found in patients with RA than in controls [201].  A similar study on 
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children and juveniles with RA conducted by Araujo et coworkers reported oxidant/anti-oxidant 
levels imbalanced where levels of lipid peroxidation products were elevated in the synovial fluid, 
while plasma antioxidant levels dropped [202].  In the study by Arajuo and colleagues, the extent 
of lipid peroxidation was estimated by measurement of peripheral plasma lipid hydro-peroxides 
that are the major initial molecular products of lipid peroxidation, and thiobarbituric acid reactive 
substances (TBARS), mostly malondialdehyde (MDA), a secondary product of lipoperoxidation 
[202].   
Selenium Studies in Animal Models 
Ren and colleagues investigated the roles of combined selenium and iodine deficiency in 
bone development as a model of Kashin-Beck osteoarthropathy [163].  They randomly divided 
Sprague-Dawley rats (n = 48) into selenium deficient diet (-SE+I), iodine deficient diet (+Se-I), 
combined selenium and iodine deficienct (-Se-I) diet, and selenium and iodine sufficient diet 
(+Se+I) groups.  Within two generations of rats (F0 and F1), they measured the growth of bone 
and cartilage, and the expression of type X collagen and parathyroid hormone-related peptide.  
They found that tibial length in –Se-I rats was significantly shorter in F1 generation rats.   In +Se-
I fed F1 rats, the thickness of the growth plate cartilage, and the proliferative zone was smaller, 
while in −Se−I rats the growth plate, and the proliferative and hypertrophic zones were also 
thinner in the F1 generation. In articular cartilage, type X collagen expression was increased in the 
deep zone in −Se−I rats of the F0 generation, and in −Se+I, +Se−I and −Se−I rats of the 
F1 generation.  Parathyroid hormone-related peptide expression was increased in the middle zone 
of −Se+I, +Se−I and −Se−I rats of both F0 and F1 generations. In the growth plate cartilage, type 
X collagen and parathyroid hormone-related peptide were expressed in the hypertrophic zone. 
Type X collagen expression was significantly reduced in −Se+I and −Se−I rats in both F0 and F1 
generations, while parathyroid hormone-related peptide expression was stronger in −Se+I, +Se−I 
and −Se−I rats in both F0 and F1 animals. The researchers concluded that combined selenium and 
iodine deficiency impaired the growth of bone and cartilage.  The changes in the expression of 
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type X collagen and parathyroid hormone-related peptide induced by combined selenium and 
iodine deficiency were comparable to measurements of type X collagen and parathyroid 
hormone-related peptide in Kashin-Beck osteoarthropathy [163].   
Turan and colleagues conducted a study to investigate the effects of dietary selenium on 
the biomechanical properties of bone noting the correlation between catalytic activity of selenium 
compounds and toxicity in past literature.  Newborn Wistar rats of both sexes were fed for 12-14 
weeks with either a control diet (225 µg Se/kg), or selenium (9.8 µg Se/kg diet) and vitamin E 
deficient, or a selenium-excess (4.2 mg Se/kg) diet and vitamin E –adequate diet.  The animals 
were housed individually in wire-bottomed cages and given deionized water with negligible 
amounts of Se (< 1 µg/L).  All groups were evaluated for the stiffness (modulus of elasticity) of 
the femur and tibia by tensile test. The tensile strength of the bones was machine tested after the 
proximal and distal ends were fixed with adhesive.  The tensile tests were performed on all 
specimens with a constant speed of 2 mm/min and the loading was of a displacement-controlled 
type using a 500-N load cell.  The force versus deflection curves obtained from the tests were 
transformed into stress versus strain diagrams.  Finally, the modulus of elasticity of each bone 
was calculated from the slope of the linear region of the stress-strain curve.  The researchers 
found that, compared to the control, the deficient and the excess groups had decreased 
biomechanical strength.  To support the biomechanical results for both experimental groups, X-
ray diffraction analysis and a Fourier transform infrared spectroscopy (FTIR) study were 
performed on the femurs and tibias.  The X-ray diffraction test on the femora and the tibia of both 
experimental groups showed possible alterations in crystallinity or a poor crystalline substance.  
The FTIR spectra of femora and tibiae from both experimental groups show a decrease in 
intensity of carbonate bands in the spectral region of 2900-3000 cm-1, and at 1750 cm-1 with 
respect to those of the controls.  The researchers concluded that the bones of both the excess and 
deficient group showed a decrease in crystallinity which was more profound for the excess group 
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in both tibia and femur.  Both the X-ray diffraction and FTIR analyses correlated very well with 
the biomechanical data [171].  
Moreno-Reyes and colleagues investigated whether growth inhibition cause by selenium 
deficiency in rats is associated with changes in bone metabolism.   Female Wistar rats on a 
selenium-deficient diet (0.005 mg selenium/kg) were mated with selenium-adequate male rats in 
house and housed individually after pregnancy was confirmed.  The pregnant dams were 
continuously fed the deficient diet through delivery and weaning.  Male pups (n = 24) were 
weaned at 21 days of age and remained on the diet until the end of the experiment (day 74).  
Control male mice were obtained in the same way but the parental generation was fed diets 
supplemented with 0.19 mg of selenium/kg.  Control and experimental mice were pair-fed.  Rats 
were sacrificed on day 74 and femurs and tibias were collected while pituitaries were dissected 
and frozen.   
To determine selenium status, plasma selenium was measured by atomic absorption 
spectrometry using the Zeeman background correction.  The researchers found reduced plasma 
selenium concentration in rats fed low selenium diet.  Rats fed low selenium diet also had 
reduced glutathione peroxidase activity by 99% (3 ± 0.3 U/mg protein vs. 574 ± 27 U/mg 
protein; p < 0.001).  To determine growth parameters, tail length and body weight of F1 
generation weaning male rats were measured once a week starting on day 21 until the end of 
experiment.  Body weight and tail length were significantly lower in the selenium-deficient rats 
two weeks after weaning, and the difference increased with age.  At the end of the experiment, 
body weight was reduced by 31% and tail length was reduced by 13% in the selenium-deficient 
rats.  The lengths of the dissected bones were also significantly reduced.   
Concentrations of plasma proteins and albumin were slightly lower in selenium-deficient 
animals (p = 0.02).  Plasma thyroid hormones and alkaline phosphatase were not significantly 
different between groups, but there was a trend (p = 0.06) toward lower T3 and lower alkaline 
phosphatase in the selenium-deficient rats.  Furthermore, the researchers found a 68% reduction 
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in pituitary GH concentrations and a 50% reduction in insulin-like growth factor I (IGF-I) in 
selenium-depleted rats.  Several markers were used by Moreno-Reyes and co-workers to gauge 
bone metabolism.  Plasma calcium concentration was lower in selenium-deficient rats while 
urinary calcium concentration from 24-hour collections was 2-fold greater compared to controls.  
Plasma and urinary phosphate did not show significant differences between groups.  Plasma IGF-
I was significantly correlated with plasma calcium in the selenium-deficient group (p = 0.025).  
Although plasma 25(OH)D3 concentrations were not different in both groups, selenium-deficient 
rats showed a 25% reduction in plasma ostecalcin concentrations and 57% reduction in urinary 
deoxypyridinoline concentrations.   Dual-energy X-ray absorptiometry was used to measure the 
BMC and BMD of the distal end of the femur and the proximal end of the tibia.  Morphometric 
measurements of left femur were taken by slicing longitudinally in the coronal plane of the distal 
end.  Trabecular bone volume and surface were measured on a SAMBA 2005 image analyzer in 
the metaphysis of the left femur.  Femur and tibia BMC and BMD were significantly reduced by 
the selenium-depleted diet and remaining significantly lower even after controlling for body 
weight in a multiple regression analysis.  Trabecular bone volume, trabecular surfaces, and 
diameter were also reduced in the selenium-deficient rats.  The osteoblast number was increased 
by 3-fold and the osteoclast number was increased by 2-fold.  The trabecular bone architecture 
was clearly deteriorated in selenium-deficient rats with fewer and thinner trabeculae.  No specific 
measures of oxidative stress or lipid peroxidation were included [189].   
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CHAPTER III 
 
 
METHODOLOGY 
This section recounts the experimental design of the study including the diet given to 
mice, and the methods of assessing Se status and bone quality.   
Animal Experiment and Study Design  
This study has a 4 x 2 factorial design (four diet groups with an LPS group and a placebo 
group) and randomization occurred as shown in Fig 3.1.  The study was approved by the 
Institutional Animal Care and Use Committee (IACUC) of Oklahoma State University (OSU).  
Second generation selenium-deficient animals were used to demonstrate the effects of Se in a 
relatively short time.   
Animal Feeding and Handling   
Forty-one timed-pregnant C57BL6 mice (Harlan, Indianapolis, IN) (60-80g) were fed a 
commercially purchased Torula yeast selenium-deficient diet (modified AIN-93G; Teklad Diets, 
Harlan Laboratories, Madison, WI) for the last 5 to 7 days of pregnancy and through lactation.  
Animals were housed in an environmentally controlled animal care facility and delivered their 
litters approximately 5-6 days after arrival.  Male pups were weaned at 23 or 24 days of age and 
randomly assigned to the depletion diet or to diets supplemented with 0.2, 2 or 4 mg/kg diet of 
Se, added as sodium selenate, for 14 weeks.  Feeding occurred on a daily basis ad libitum at about 
5 g diet/day/mouse.  Clean water was also provided every 2-3 days and bedding was changed 
weekly.   
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Figure 3.1: Study design randomization flowchart 
Preparation of the Experimental Diets   
The experimental diets followed a modification of the recommendations of the American 
Institute of Nutrition (AIN-93) for growing rodents and were isocaloric and isonitrogenous [1].  
Minerals and vitamins were equivalent for the four different diets, except for selenium, which 
was added or omitted according to the experimental design.  The basal Se depletion diet (Torula 
yeast-based, approximately 0.02mg Se/kg diet) was produced commercially, while the 
supplemented diets were prepared either commercially or in-house from a basal mix at the 
Nutritional Sciences laboratory at Oklahoma State University in 5 kg batches in a commercial 
mixer.  Selenium was added in the form of sodium selenate at 0.2, 2.0 or 4.0 mg Se/kg.   Diets 
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were refrigerated until being partitioned for feeding.  The composition of the experimental diets is 
presented in Table 3.1. 
Table 3.1. Composition of the experimental diets  
Added Se (mg/kg diet) 
Ingredients (g/kg) 0 Se 0.2 Se 2.0 Se 4.0 Se 
Torula yeast 340 340 340 340 
L-cysteine 3 3 3 3 
Dextrose, monohydrate 399.02 399.02 399.02 399.02 
Sucrose 100 100 100 100 
Soybean oil 60 60 60 60 
Cellulose 50 50 50 50 
Mineral mix 35 35 35 35 
Vitamin mix AIN-93-VX 10 10 10 10 
Choline bitartrate 2.5 2.5 2.5 2.5 
 
Chronic Inflammation   
At 96-98 days of age mice were randomly assigned within diet groups to placebo or to 
lipopolysaccharide (LPS) (E. coli Serotype 0127:B6) treatment to produce inflammatory stress.  
Time release pellets (0 or 0.1 µg/g body weight/d) were implanted subcutaneously after 
anesthetization with intraperitoneal injections mixed ketamine (10 mg/mL) and xylazine (1 
mg/mL) at a concentration of 0.006 mL/10 g body weight.  Body weight was taken on the day of 
implantation as well as at 14-days after implantation.  
Necropsy of Pups   
All necessary surgical instruments were autoclaved and preparations for tissue harvests 
and collection of blood were organized before the day of necropsy.  The day before the necropsy, 
the pups were fasted overnight for 12 hours and their body weight was recorded. On the day of 
necropsy, each mouse was anesthetized with injections of mixed ketamine (10 mg/mL) and 
xylazine (1 mg/mL) at a concentration of 0.006 mL/10 g body weight.  PIXImus whole body 
scans were taken.  Blood was drawn with syringes pre-coated with EDTA from the carotid artery 
before dissection for harvesting of organs and tissues.  The blood was held on ice for up to 2-3 
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hours until the end of necropsy.  Plasma was obtained from whole blood by centrifugation at 
4,000 rpm (Eppendorf #5415R) for 20 min and stored at -80°C.  Liver was placed in liquid 
nitrogen and stored at -20°C.  The right tibia and spine were excised and stored at -20°C.  
Determination of Weight Change, Organ Weight, and Body Lean and Fat Mass  
Weight fluctuations were assessed by calculating weight data gathered during the 30 days 
of LPS treatment.  Harvested organs were weighed immediately before storage.  Body lean mass 
and fat weights were assessed using PIXImus. 
Laboratory Analyses 
Plasma Gpx 
Se status was measured by plasma glutathione peroxidase 3 activity using a kinetic 
enzyme assay (Product No. FR17, Oxford Biomedical Research, Inc. Oxford, MI).  The assay 
was conducted at room temperature (20 - 25°C) and spectrophotometric readings were done at 
340 nm.  The spectrophotometer was zeroed at 340 nm with deionized water.  The plasma 
samples from mice fed 0.2, 2 and 4 mg/kg diet were diluted 1:10 using assay buffer provided in 
the kit.  The plasma samples from mice fed the selenium-depleted diet were not diluted with 
assay buffer.  An appropriate volume of assay buffer, pre-diluted NADH reagent and sample were 
pipetted into the cuvette and placed in the spectrophotometer followed by addition of tert-butyl 
hydroperoxide and mixed by pipetting.  The GPX coupled reduction of tert-butyl hydroperoxide 
from the oxidation of NADPH by glutathione reductase and concomitant oxidation was 
monitored for three minutes in a spectrophotometer by the decrease in absorbance at 340 nm.  In 
each reading, the rate of decrease in A340/minute was calculated and the net rate for the sample 
was calculated by subtracting the rate from the water blank.  The net A340/min for each sample 
was then converted to NADPH consumed.  One unit of GPX is expressed as the amount of GPX 
needed to oxidize 1 µmol of NADPH per min.  The value for each sample was corrected for 
dilution factors and expressed as GPX µM/mL.  
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Bone Analyses 
Tibia and vertebral columns were stored at -20°C.  Individual bones were thawed for 15 
min at room temperature before analysis.   
Bone Measurement by Microcomputed Tomography (µCT) 
After bones were properly thawed and defleshed they were placed in 12 mm or 16 mm 
µCT tubes with either water or 10% ethanol and pre-scanned in the µCT-40 (Scanco Medical AG, 
Zurich, Switzerland) to confirm repositioning.  The microarchitecture of the trabeculae of 
vertebra (L4) and proximal tibia were scanned using microcomputed tomography (µCT).  The 
vertebral body was scanned for a region VOI distally from the proximal growth plate at medium 
resolution (16 µm per slice), while the proximal tibial was scanned distally at high resolution for 
a minimum of 150 slices at 12 µm per slice.  For cortical bone analysis, the midshaft region 
calculated precisely at the middle of the tibia was scanned at 12 µm per slice for a minimum of 45 
slices.   
Bone Densitometry by PIXImus 
Two-dimensional analysis of tibial and L4 bone mineral area (BMA), bone mineral 
content (BMC), and bone mineral density (BMD) were assessed by the PIXImus (Lunar Corp. 
Madison, WI).  BMC is an estimate of the amount of mineral present in the bone, BMA estimates 
the two-dimensional area occupied by bone, and BMD is equal to BMC divided by BMA.   
Bone Structure Analysis   
The microarchitecture of the trabeculae of the L4 vertebra, and the proximal tibia were 
analyzed using µCT.  Contours were placed on L4 vertebrae to identify a VOI beginning at 10 
slices (16 µm per slice) away from the growth plate in order to include in the VOI only the 
secondary spongiosa within the two growth plates.  µCT analysis for vertebra was performed at a 
threshold of 315, a sigma of 0.7, and a gauss support of 1.0.   
Contours were placed on a total of 100 consecutive tomographic slices (12 µm per slice) 
of tibia beginning at 10 slices from the growth plate (sigma = 0.7, threshold = 360, gauss support 
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= 1.0).  Contours were also placed on 30 slices scanned from the midshaft region of the tibia to 
analyze cortical bone volume, thickness, and porosity.   
Bone morphometric parameters including cortical porosity, trabecular bone relative 
volume (BV/TV), trabecular number (TbN), trabecular separation (TbSp), and trabecular 
thickness (TbTh), as well as the structural model index (SMI), connectivity density (ConnD) of 
the trabeculae, and the degree of anisotropy (DA) were obtained for L4 and tibia. 
Bone Biomechanical Tests  
Bone Strength Simulation Using Finite Element Analysis by Micro-CT   
The finite element analysis (FEA) simulates compression of a region of interest (ROI) of 
bone to determine the response to pressure.  The FEA simulation software (v. 1.16), is used in 
combination with the micro-computed tomography (µCT) histomorphometric data.  
Biomechanical properties of tibia and the L4 vertebra were modeled using a VOI composed of 
trabecular bone, which was subjected to a high friction compression test in the z direction.  This 
allowed determination of mechanical properties such as average strain, total force and 
physiological force, stiffness, size independent stiffness, and von Mises stress of the trabecular 
cores.   
Liver Ash Weight and Mineral Content Using Inductively Coupled Plasma-mass 
Spectroscopy 
Liver samples were ashed following a modified protocol from Hill and colleague [2].  
Liver tissue was ashed in duplicate to determine the Se content with inductively coupled plasma 
mass spectrometry (ICP-MS).  Excised liver previously stored at -80°C was kept on ice to remove 
approximately 0.1 g of tissue.  The liver sample was oven dried overnight at 100°C in acid-
washed, glass borosilicate tubes. Dry weights of the samples were taken, and acid digestion was 
conducted with 1 part concentrated nitric acid (HNO3) and 5-6 parts hydrogen peroxide H2O2 
added every 30-60 minutes while the samples were being heated continuously at 95°C.  Acid 
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digestion continued until the tissue samples turned a solid white.   Se concentrations were 
determined in triplicate using ICP-MS (ELAN 9000, PerkinElmer SCIEX, Waltham, MA).   
Statistical Analyses  
Data were analyzed using SAS (Statistical Analysis System) version 9.3 (SAS Institute 
Inc., Cary, NC).  Two-way ANOVA was performed using PROC GLM followed by post hoc 
analysis with Fisher’s least significant differences test for means separation when F values were 
significant.  Data are represented as means ± SEM and p < 0.05 was considered significant.  
When interaction terms were significant, data are presented graphically.   
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CHAPTER IV 
 
 
RESULTS AND DISCUSSION 
This section recounts the results of the study and discusses the implications of the results 
with respect to the existing literature.   
Results 
Body Weight, inflammation, and diet indicator 
Body Weight and Bone Density 
There were no statistically significant differences in body weight by dietary Se intake at d 
120 (p > 0.05, Table 4.1).  Some weight fluctuations were seen in both the placebo and LPS 
group at 14 days after LPS implantation (p = 0.002), but by necropsy (d 120) the weight 
differences were no longer significant but showed a trend for lower weight in the LPS group (p = 
0.07).  This indicates that LPS treatment and/or Se deficiency and supplementation did markedly 
affect growth of the mice.  BMD and BMC measurements were reduced by LSP treatment when 
compared to control (p = 0.02).  Mice in the Se adequate diet had lower BMD (p = 0.004) and 
BMC (p < 0.0001) compared to mice in the Se deficient and supplemented groups. 
Organs Weights 
 Kidney and thymus weight showed no significant differences by dietary Se intake or by 
LPS at 120 days of age at necropsy (p > 0.05, Table 4.2).  Thymus weight, however, tended to be 
higher for LPS (0.050 g) compared to placebo group (0.043 g) (p = 0.06).  Liver weight was 
significantly affected by diet (p = 0.04) with mice in the 4.0 mg Se/kg diet group having the 
smallest liver indicating a possible toxicity effect.   
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Table 4.1 Body weight and bone density of mice fed supplemental Se with and without LPS (mean ±SEM) 
Treatment means 
Added Se 
(mg/kg diet) Pellet n 
Body Weight 
at LPS(g) 
Body Weight at 
14d post LPS (g) 
Body Weight 
at necropsy (g) BMD (g/cm2) BMC (g/cm2) 
0 
placebo 10 25.2 ± 0.3  25.6 ± 0.2  25.7 ± 0.2  0.052 ± 0.001  0.58 ± 0.01 
LPS 10 25.0 ± 0.6  24.7 ± 0.4  24.1 ± 0.5  0.050 ± 0.001  0.55 ± 0.02 
0.2 
placebo 11 25.5 ± 0.4  25.7 ± 0.5  25.5 ± 0.5  0.049 ± 0.000  0.53 ± 0.01 
LPS 10 24.5 ± 0.3  24.2 ± 0.2  25.1 ± 0.2  0.047 ± 0.000  0.50 ± 0.01 
2 
placebo 11 25.8 ± 0.5  26.2 ± 0.5  25.7 ± 0.6   0.050 ± 0.001  0.55 ± 0.02 
LPS 10 26.3 ± 0.6  25.5 ± 0.6  26.0 ± 0.7  0.050 ± 0.001 0.55 ± 0.02 
4 
placebo 10 25.8 ± 0.4  25.9 ± 0.5  25.2 ± 0.4  0.050 ± 0.001 0.56 ± 0.01 
LPS 10 25.4 ± 0.4  25.1 ± 0.3  24.8 ± 0.4  0.050 ± 0.001 0.57 ± 0.02 
Diet means 
Added Se 
(mg/kg diet) N 
Body Weight 
at LPS(g) 
Body Weight at 
14d post LPS (g) 
Body Weight 
at necropsy (g) BMD (g/cm2) BMC (g/cm2) 
0 20 25.1 ± 0.3 25.1 ± 0.2 24.9 ± 0.3 0.051 ± 0.001a  0.56 ± 0.01a  
0.2 21 25.0 ± 0.3 25.0 ± 0.3 25.5 ± 0.3 0.048 ± 0.000b  0.51 ± 0.01b  
2 21 26.0 ± 0.4 25.9 ± 0.4 25.9 ± 0.4 0.049 ± 0.001a  0.55 ± 0.01a  
4 20 25.6 ± 0.3 25.5 ± 0.3 25.0 ± 0.3 0.050 ± 0.001a  0.56 ± 0.01a  
LPS means 
Placebo 42 25.6 ± 0.2 25.9 ± 0.2a 25.6 ± 0.2 0.051 ± 0.001a  0.55 ± 0.01a  
LPS 40 25.3 ± 0.3 24.9 ± 0.2b  25.0 ± 0.3 0.049 ± 0.001b  0.54 ± 0.01b  
p-values 
Se  0.09 0.17 0.16 0.004 <0.0001 
LPS 0.39 0.002 0.07 0.02 0.02 
Se x LPS 0.48 0.80 0.27 0.55 0.33 
Means in a column with superscripts not sharing a common letter are significantly different from each other at p < 0.05. 
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Table 4.2:  Selected organ weights of mice fed supplemental Se with and without LPS (mean ±SEM) 
Treatment means 
Added Se 
(mg/kg diet) Pellet n Liver (g) n Kidney (g) n Thymus (g) 
0 
placebo 9 1.31 ± 0.02 10 0.17 ± 0.00 10 0.04 ± 0.00 
LPS 10 1.36 ± 0.02 10 0.17 ± 0.00 10 0.05 ± 0.00 
0.2 
placebo 11 1.39 ± 0.05 11 0.16 ± 0.00 11 0.04 ± 0.00 
LPS 10 1.39 ± 0.03 10 0.16 ± 0.00 10 0.05 ± 0.00 
2 
placebo 11 1.30 ± 0.04 11 0.17 ± 0.01 11 0.05 ± 0.00 
LPS 9 1.38 ± 0.04 9 0.16 ± 0.01 10 0.05 ± 0.00 
4 
placebo 10 1.30 ± 0.04 9 0.17 ± 0.01 10 0.05 ± 0.00 
LPS 11 1.32 ± 0.05 11 0.17 ± 0.01 11 0.05 ± 0.00 
Diet means 
Added Se 
(mg/kg diet) N Liver (g) n Kidney (g) n Thymus (g) 
0 19 1.35 ± 0.00a  20 0.17 ± 0.00 20 0.05 ± 0.00 
0.2 21 1.39 ± 0.03a  21 0.16 ± 0.00 21 0.05 ± 0.00 
2 20 1.33 ± 0.03ab  20 0.17 ± 0.00 21 0.05 ± 0.00 
4 21 1.27 ± 0.03b  20 0.17 ± 0.00 21 0.05 ± 0.00 
LPS means 
Placebo 41 1.31 ± 0.02 41 0.17 ± 0.00 42 0.04 ± 0.00 
LPS 40 1.36 ± 0.20 40 0.16 ± 0.00 41 0.05 ± 0.00 
p-values 
Se  0.04 0.17 0.89 
LPS 0.12 0.22 0.06 
Se x LPS 0.55 0.87 0.40 
Means in a column with superscripts not sharing a common letter are significantly different from each other at p < 0.05.
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Plasma Se and Gpx3 Activity 
Plasma Se of mice from different experimental diets at necropsy showed significant 
differences by diets supplemented with Se ( 0.0; 0.2; 2.0 and 4.0 mg Se/kg diet) (p = 0.02) 
(Table 4.3). Mice fed the Torula yeast Se-deficient diet with no added Se had significantly lower 
plasma Se compared with other groups (Table 4.3). However, plasma Se was not significantly 
affected by LPS. 
When mice in different dietary Se groups were compared, the group that consumed no 
added dietary Se showed significantly lower plasma Gpx activity than the other three dietary Se 
groups containing 0.2, 2.0 and 4.0 mg Se /kg of diet (p < 0.0001, Table 4.2). The diet with 0.2 
mg Se added/kg diet represented the control diet and additional selenium supplementation did 
not increase Gpx activity.  Also, LPS had no significant effect of Gpx activity  
Liver Se content 
 To examine the concentrations of tissue Se in mice fed different dietary groups, ~0.1 g of 
wet liver was ashed and measured for Se content by ICP-MS.  The Se content of liver (Table 
4.4) in Se deficient mice was significantly lower than that of other dietary groups (p <0.0001).   
The Se content in two experimental diet groups (2.0 mg Se/kg  and 4.0 mg Se/kg) are very 
similar, while the Se content of mice in the Se-adequate diet group (0.2 mg Se/kg) was  < 40% 
less than the two Se supplemented groups though this repression did not reach the level of 
statistical significance. 
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Table 4.3:  Plasma Se content and Gpx3 activity in mice fed supplemental Se with and 
without LPS (mean ± SEM) 
Treatment means 
Added Se 
(mg/kg diet) Pellet n Plasma Se (mg/L) n Gpx (mU/L) 
0 
placebo 5 0.095 ± 0.03 5 32.5 ± 11.7 
LPS 5 0.103 ± 0.05 5 35.6 ± 5.4 
0.2 
placebo 4 0.260 ± 0.04 5 977.5 ± 148.4 
LPS 5 0.192 ± 0.05 5 725.4 ± 208.2 
2 
placebo 4 0.168 ± 0.06 5 937.4 ± 100.5 
LPS 5 0.247 ± 0.04 5 880.8 ± 144.0 
4 
placebo 5 0.188 ± 0.03 5 1039.2 ± 161.9 
LPS 5 0.206 ± 0.03 5 1010.4 ± 65.9 
Diet means 
Added Se 
(mg/kg diet) n Plasma Se (mg/L) n Gpx (mU/L) 
0 10 0.099 ± 0.03b 10 34.1 ± 6.1
b
 
0.2 9 0.222 ± 0.03a 10 851.5 ± 127.6
a
 
2 9 0.212 ± 0.03a 10 909.1 ± 83.3
a
 
4 10 0.197 ± 0.02a 10 1024.8 ± 82.5
a
 
LPS means 
Placebo 38 0.187 ± 0.02 40 746.7 ± 110.0 
LPS 40 0.173 ± 0.02 40 663.1 ± 105.1 
p-values 
  Plasma Se Gpx 
Se  0.02 <0.0001 
LPS 0.75 0.36 
Se x LPS 0.4 0.74 
Means in a column with superscripts not sharing a common letter are significantly different from each other at p < 0.05. 
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Table 4.4: Liver Se concentration in mice fed supplemental Se with and without LPS (mean 
± SEM) 
Treatment means 
Added Se (mg/kg diet) Pellet n Se in Liver (ng/g wet wt) 
0 
placebo 7 114.3 ± 94.6 
LPS 3 48.2 ± 15.1 
0.2 
placebo 4 803.6 ± 164.8 
LPS 5 850.1 ± 105.7 
2 
placebo 5 1673.1 ± 509.0 
LPS 5 1242.0 ± 80.2 
4 
placebo 5 1399.4 ± 167.2 
LPS 5 1497.8 ± 80.5 
Diet means 
Added Se (mg/kg diet) n Se in Liver (ng/g wet wt) 
0 10 94.5 ± 65.6b 
0.2 9 829.4 ± 87.7a 
2 10 1457.6 ± 253.3a 
4 10 1448.9 ± 89.0a 
LPS means 
Placebo 18 922.7 ± 189.1 
LPS 21 1005.2 ± 125.8 
p-Values 
Se  < 0.0001 
LPS 0.57 
Se x LPS 0.60 
Means in a column with superscripts not sharing a common letter are significantly different from each other at p < 0.05. 
 
Bone Microarchitecture  
 To examine alterations in trabecular bone and/or cortical bone, tibia and fourth lumbar 
vertebrae (L4) were analyzed using µCT.  As a measure of trabecular bone microarchitecture, 
SMI quantifies the organization of trabecular bone where a value of 0 signifies completely plate 
like trabeculae, and a value of 3 represents all rod-like trabeculae.  Connectivity density 
measures the number of connected trabeculae in a specific volume.  In cortical bone of tibia, both 
BV/TV (p = 0.07) and cortical thickness (p = 0.06) tended to be reduced by LPS treatment.  
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Cortical porosity tended to be increased by LPS (p = 0.07).  The Se-adequate diet also tended to 
have a negative effect on cortical thickness (p = 0.06) (Table 4.5) and mice in the Se deficient 
group had slightly thicker trabeculae than control animals.   
In trabecular bone of tibia, BV/TV (p = 0.004), and trabecular number (p < 0.0001) were 
both significantly reduced by LPS treatment (Table 4.6).  LPS also significantly increased 
trabecular separation (p < 0.0001).  There was an interaction effect of Se and LPS on 
connectivity density (p = 0.01) and SMI (p = 0.02) (Figure 4.1).  LPS significantly lowered 
connectivity density in the selenium-depleted group, but not in the other diet groups.  In the 
deficient diet group, SMI was significantly increased by LPS indicating more rod-like structure, 
while other diet groups were not significantly affected (Table 4.6).   
In trabecular tissue of the L4 section of spine, BV/TV (p = 0.01), connectivity density (p 
= 0.0001), and trabecular number (p = 0.001) were significantly reduced by LPS treatment 
(Table 4.7).  SMI (p < 0.0001) and trabecular separation (p < 0.0001) were significantly 
increased by LPS.  Mice fed the Se depleted diet had significantly higher BV/TV, connectivity 
density, and trabecular number, and had significantly lower SMI (p = 0.03), and trabecular 
separation (p = 0.002) than mice on the other dietary treatments.  Taken together, these data 
show that LPS treatment primarily has a negative effect on trabecular microarchitecture similar 
to the trend seen in cortical bone.  The effect of diet can primarily be seen only in the Se 
deficient mice.  These mice had significantly better microarchitecture when compared to bones 
of mice in the other dietary treatments.   
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Table 4.5:    Effects of LPS and diet on µCT measurements on tibia cortical bone volume 
fraction, cortical porosity and cortical thickness (means ± SEM) 
Treatment means 
Added Se 
(mg/kg diet) Pellet n BV/TV (%) 
Cortical 
Porosity (%) 
Cortical 
Thickness (mm) 
0 
placebo 10 95.4 ± 0.2 4.6 ± 0.2 0.213 ± 0.004 
LPS 10 92.4 ± 24.3 7.6 ± 2.4 0.200 ± 0.004 
0.2 
placebo 9 95.1 ± 0.1 4.9 ± 0.1 0.199 ± 0.004 
LPS 9 94.8 ± 0.2 5.2 ± 0.2 0.192 ± 0.004 
2 
placebo 10 94.8 ± 0.1 5.2 ± 0.1 0.203 ± 0.005 
LPS 10 92.1 ± 2.6 7.9 ± 2.6 0.196 ± 0.004 
4 
placebo 10 94.7 ± 0.2 5.3 ± 0.2 0.198 ± 0.004 
LPS 10 93.7 ± 1.3 6.3 ± 1.3 0.202 ± 0.004 
Diet means 
Added Se 
(mg/kg diet) n BV/TV (%) 
Cortical 
Porosity (%) 
Cortical 
Thickness (mm) 
0 20 93.9 ± 1.2 6.1 ± 1.2 0.207 ± 0.003 
0.2 18 95.0 ± 0.1 5.0 ± 0.1 0.196 ± 0.003 
2 20 93.4 ± 1.3 5.8 ± 0.6 0.199 ± 0.003 
4 20 94.2 ± 0.6 5.8 ± 0.6 0.200 ± 0.003 
LPS means 
Placebo 39 95.0 ± 0.1 5.0 ± 0.1 0.203 ± 0.002 
LPS 39 93.2 ± 0.9 6.8 ± 1.0 0.198 ± 0.002 
p-values 
Se      0.74 0.74 0.06 
LPS     0.07 0.07 0.06 
Se x LPS     0.72 0.45 0.2 
Means in a column with superscripts not sharing a common letter are significantly different from each other at p < 0.05. 
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Table 4.6:  Effects of LPS and diet on µCT measurements of tibia trabecular bone parameters in mice (means ± SEM) 
Treatment means 
Added Se 
(mg/kg diet) Pellet N BV/TV (%) 
Connectivity  
Density (1/mm3) SMI 
Trabecular 
Number (1/mm3) 
Trabecular 
Thickness (mm) 
Trabecular 
Separation (mm) 
0 
placebo 10 18.8 ± 0.8 292.65 ± 30.15a 1.50 ± 0.11d 5.986 ± 0.159 0.0441 ± 0.0009 0.159 ± 0.005 
LPS 10 14.0 ± 1.2 180.63 ± 14.03b 2.03 ± 0.11ab 5.183 ± 0.106 0.0448 ± 0.0017 0.185 ± 0.004 
0.2 
placebo 9 15.5 ± 1.2 155.53 ± 15.60bc 1.87 ± 0.09abc 5.039 ± 0.154 0.0049 ± 0.0016 0.190 ± 0.006 
LPS 10 11.6 ± 1.2 113.91 ± 11.50c 2.15 ± 0.11a 4.556 ± 0.117 0.0457 ± 0.0021 0.213 ± 0.006 
2 
placebo 10 15.4 ± 1.4 150.92 ± 15.50bc 1.86 ± 0.13abc 4.942 ± 0.111 0.0494 ± 0.0019 0.193 ± 0.005 
LPS 10 14.2 ± 1.3 157.49 ± 16.99bc 1.84 ± 0.09abc 4.726 ± 0.160 0.0474 ± 0.0021 0.206 ± 0.008 
4 
placebo 10 16.2 ± 4.1 191.25 ± 21.29b 1.77 ± 0.13bcd 5.240 ± 0.133 0.0467 ± 0.0015 0.181 ± 0.005 
LPS 9 15.7 ± 1.2 173.07 ± 16.60b 1.64 ± 0.14cd 4.788 ± 0.163 0.0488 ± 0.0017 0.203 ± 0.007 
Diet means 
Added Se 
(mg/kg diet) N BV/TV (%) 
Connectivity  
Density (1/mm3) SMI 
Trabecular 
Number (1/mm3) 
Trabecular 
Thickness (mm) 
Trabecular 
Separation (mm) 
0 20 16.4 ± 0.9 236.64 ± 20.66 1.76 ± 0.10 5.584 ± 0.131a 0.0444 ± 0.0009 0.172 ± 0.004b 
0.2 19 13.4 ± 0.9 133.63 ± 10.49 2.02 ± 0.08 4.785 ± 0.109b 0.0472 ± 0.0013 0.202 ± 0.005a 
2 20 14.8 ± 0.9 154.21 ± 11.22 1.85 ± 0.08 4.834 ± 0.098b 0.0484 ± 0.0014 0.200 ± 0.005a 
4 19 16.0 ± 0.9 182.64 ± 13.49 1.71 ± 0.10 5.026 ± 0.114b 0.0477 ± 0.0011 0.192 ± 0.005a 
LPS means 
Placebo 39 16.5 ± 0.6 a  198.67 ± 13.99 1.75 ± 0.06 5.308 ± 0.095a 0.0472 ± 0.0008 0.181 ± 0.003b 
LPS 39 13.8 ± 0.6b 155.85 ± 8.29 1.92 ± 0.06 5.059 ± 0.046b 0.0466 ± 0.0010 0.202 ± 0.025a 
p-Values 
Se  0.098 <0.0001 0.06 <0.0001 0.11 <0.0001 
LPS 0.004 0.003 0.05 <0.0001 0.64 <0.0001 
Se x LPS 0.24 0.01 0.02 0.21 0.43 0.69 
Means in a column with superscripts not sharing a common letter are significantly different at p < 0.05.
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Table 4.7:  Effects of LPS and diet on µCT measurements of L4 trabecular bone parameters in mice (means ± SEM) 
 
Means in a column with superscripts not sharing a common letter are significantly different from each other at p < 0.05. 
Treatment means 
Added Se 
(mg/kg diet) Pellet N 
BV/TV 
(%) 
Connectivity  
Density (1/mm3) SMI 
Trabecular 
Number (1/mm3) 
Trabecular 
Thickness (mm) 
Trabecular 
Separation (mm) 
0 
placebo 10 21.4  ± 0.8 291.67 ± 15.36 1.331 ± 0.076 5.638 ± 0.078 0.046 ± 0.0009 0.172 ± 0.003 
LPS 10 17.9 ± 1.1 226.87 ± 10.17 1.704 ± 0.071 5.277 ± 0.101 0.044 ± 0.001 0.187 ± 0.001 
0.2 
placebo 11 18.7 ± 0.8 241.31 ± 11.86 1.528 ± 0.057 5.353 ± 0.105 0.043 ± 0.001 0.183 ± 0.004 
LPS 11 14.7 ± 0.9 176.02 ± 11.00 1.965 ± 0.068 4.887 ± 0.077 0.042 ± 0.001 0.203 ± 0.003 
2 
placebo 10 17.9 ± 1.2 219.19 ± 12.24 1.633 ± 0.112 5.230 ± 0.104 0.044 ± 0.001 0.188 ± 0.004 
LPS 10 16.7 ± 1.1 204.97 ± 11.36 1.782 ± 0.085 5.054 ± 0.085 0.044 ± 0.002 0.196 ± 0.004 
4 
placebo 10 18.1 ± 0.9 239.30 ± 14.49 1.558 ± 0.087 5.290 ± 0.100 0.043 ± 0.0009 0.186 ± 0.005 
LPS 10 17.3 ± 0.9 190.49 ± 6.45 1.808 ± 0.053 5.035 ± 0.068 0.046 ± 0.002 0.195 ± 0.003 
Diet means 
Added Se (mg/kg diet) n 
BV/TV 
(%) 
Connectivity  
Density (1/mm3) SMI 
Trabecular 
Number (1/mm3) 
Trabecular 
Thickness (mm) 
Trabecular 
Separation (mm) 
0 20  19.8 ± 0.7a  259.27 ± 8.57a  1.517 ± 0.056b 5.458 ± 0.066a 0.045 ± 0.0009 0.179 ± 0.003a 
0.2 22  16.7 ± 0.6b  208.66 ± 8.17b  1.746 ± 0.054a 5.120 ± 0.063b 0.043 ± 0.0009 0.193 ± 0.003b 
2 10  17.3 ± 0.6b  212.08 ± 8.37b  1.707 ± 0.055a 5.142 ± 0.064b 0.044 ± 0.0009 0.192 ± 0.003b 
4 10  17.7 ± 0.7b  214.90 ± 8.57b  1.683 ± 0.056a 5.163 ± 0.066b 0.044 ± 0.0009 0.190 ± 0.003b 
LPS means 
Placebo 41 19.1 ± 0.5a 247.03 ± 7.68a 1.516 ± 0.045b 5.374 ± 0.053a 0.044 ± 0.0006 0.182 ± 0.002b 
LPS 41 16.6 ± 0.5b 199.01 ± 5.67b 1.818 ± 0.037a 5.059 ± 0.046b 0.044 ± 0.0008 0.195 ± 0.002a 
p-Values 
Se  0.01 0.0001 0.03 0.001 0.35 0.002 
LPS 0.0005 <0.0001 <0.0001 <0.0001 0.96 <0.0001 
Se x LPS 0.21 0.11 0.26 0.4 0.17 0.44 
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Bone Biomechanics 
 The influences of chronic inflammation and graded levels of Se in the diet on trabecular 
bone biomechanical properties were evaluated using finite element analysis (FEA) of µCT 
images of the proximal tibia metaphysis and L4 of spine.  Diet had a significant effect on tibia 
biomechanical properties (Table 4.8).  Compressive strength of the trabecular bone from tibia 
was significantly lower in mice fed adequate diet (0.2 Se mg/kg) compared to the other diet 
groups (p = 0.04).  Bone stiffness was also reduced in mice fed adequate diet (p = 0.04).  The 
average von Mises stress was increased in animals fed the adequate Se diet (p = 0.0001).   
In L4, an interaction effect was present (Figure 4.2) for most of the biomechanical 
properties (Table 4.9).  Size independent stiffness was significantly reduced by LPS (p = 0.03).  
In strain, an interaction effect can be seen between diet and LPS. In the adequate diet group only, 
LPS significantly reduced average strain and average apparent strain.  In bone from mice in the 
deficient diet group, LPS resulted in significantly reduced physiological force.  The simulated 
compression tests demonstrated that diet had a more significant effect than LPS on tibia strength 
and stiffness, where mice on the sufficient diet had lower quality bone and Se supplementation 
did not provide additional benefit.  LPS treatment resulted in compromised trabecular strain in 
spine mostly in mice fed adequate Se diet (0.2 Se mg/kg).   The von Mises measurements in the 
LPS treated group of the 0.2 Se mg/kg diet group were the highest.   
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Table 4.8:  Effects of LPS and diet on biomechanical properties of tibia- physiological 
force, stiffness and von Mises stresses in mice (means ± SEM) 
Treatment means 
Added Se 
(mg/kg diet) Pellet n 
Physiological 
Force (N) Stiffness (N/mm) 
von Mises Stress 
(MPa) 
0 
placebo 10 0.0487 ± 0.0044 2704.30 ± 242.32 34.13 ± 7.95 
LPS 10 0.0364 ± 0.0046 2025.10 ± 256.88 46.44 ± 11.24 
0.2 
placebo 9 0.0371 ± 0.0059 2059.78 ± 329.89 75.16 ± 9.26 
LPS 9 0.0243 ± 0.0042 1349.67 ± 230.68 119.18 ± 20.04 
2 
placebo 9 0.0429 ± 0.0073 2436.22 ± 404.93 39..09 ± 9.52 
LPS 11 0.0470 ± 0.0073 2608.64 ± 406.02 51.037 ± 13.00 
4 
placebo 10 0.0477 ± 0.0076 2651.40 ± 421.77 42.66 ± 14.64 
LPS 10 0.0487 ± 0.0061 2706.90 ± 336.64 36.12 ± 8.04 
Diet means 
Added Se (mg/kg diet) n 
Physiological 
Force (N) Stiffness (N/mm) 
von Mises Stress 
(MPa) 
0 20 0.0426 ± 0.0034a 2364.70 ± 188.69a 40.38 ± 6.85b 
0.2 18 0.0307 ± 0.0038b 1704.72 ± 213.41b 97.17 ± 11.96a 
2 20 0.0456 ± 0.0051a 2531.05 ± 281.28a 45.66 ± 8.24b 
4 20 0.0482 ± 0.0047a 2679.15 ± 262.70a 39.39 ± 7.16b 
LPS means 
Placebo 38 0.0445 ± 0.0032 2474.24 ± 175.57 47.27 ± 5.42 
LPS 40 0.0397 ± 0.0032 2204.05 ± 177.81 61.49 ± 8.19 
p-values 
Se  0.04 0.04 0.0001 
LPS 0.23 0.23 0.07 
Se x LPS 0.42 0.42 0.22 
Means in a column with superscripts not sharing a common letter are significantly different from each other at p < 0.05. 
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Figure 4.1:  Diet and LPS interaction for proximal tibia connectivity density (A) and SMI 
(B).  The four dietary treatment groups (0.0 mg Se/kg diet, 0.2 mg Se/kg diet, 2.0 mg Se/kg diet, 
4.0 mg Se/kg diet) are separated by LPS and placebo groups to better show the interactive effect 
between diet and LPS.  Bars not sharing a common letter are significantly different from each 
other at p < 0.05.
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Table 4.9:  Effects of LPS and diet on biomechanical properties of spine - average apparent strain, size independent stiffness, 
physical force, von Mises stress in mice (means ± SEM) 
Treatment means 
Added Se 
(mg/kg diet)  Pellet  n  Average Apparent Strain  Size Independent Stiffness  Physiological Force (N)  von Mises Stress  
0 
placebo  10 0.277 ± 0.014a  6.424 ± 0.449  0.0179 ± 0.0012a  132.36 ± 4.91c  
LPS  10 0.223 ± 0.106a  4.263 ± 0.647  0.0116 ± 0.0019bc  189.63 ± 17.58ab  
0.2 
placebo  10 0.492 ± 0.132a  4.416 ± 0.662  0.0115 ± 0.0016bc  183.97 ± 14.22bc  
LPS  10 0.183 ± 0.015b  2.642 ± 0.262  0.0071 ± 0.00070c  244.73 ± 15.93a  
2 
placebo  12 0.217 ± 0.019a  4.223 ± 0.544  0.0114 ± 0.0015bc  194.31 ± 26.02ab  
LPS  10 0.221 ± 0.019a  3.749 ± 0.606  0.0103 ± 0.0017bc  208.09 ± 17.20ab  
4 
placebo  10 0.218 ± 0.024a  4.108 ± 0.685   0.0111 ± 0.0018bc  206.74 ± 31.51ab  
LPS  11 0.261 ± 0.022a  4.890 ± 0.615  0.0140 ± 0.0018ab  169.37 ± 13.41bc  
Diet means 
Added Se (mg/kg diet)  n  Average Apparent Size Independent Stiffness  Physiological Force (N)  von Mises Stress  
0 20 0.250 ± 0.014  5.343 ± 0.457a  0.0148 ± 0.0013  160.00 ± 11.05  
0.2 20 0.338 ± 0.074  3.529 ± 0.402b  0.0093 ± 0.0010  208.83 ± 15.50  
2 22 0.219 ± 0.013  4.008 ± 0.399b  0.0109 ± 0.0011  200.57 ± 15.92  
4 21 0.241 ± 0.017  4.518 ± 0.455ab  0.0126 ± 0.0013  187.17 ± 16.65  
LPS 
Placebo  42 0.297 ± 0.036  4.766 ± 0.319a  0.0129 ± 0.0009  177.43 ± 12.20  
LPS  41 0.223 ± 0.011  3.910 ± 0.299b  0.0108 ± 0.0009  202.13 ± 8.87  
p-values 
Se   0.08 0.02 0.008 0.11 
LPS  0.02 0.03 0.05 0.07 
Se x LPS  0.002 0.05 0.03 0.05 
Means with superscripts not sharing a common letter are significantly different from each other at p < 0.05.
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Figure 4.2:  Diet and LPS interaction for L4 average apparent strain (A) physiological force (B) and 
von Mises stress (C).  The four dietary treatment groups (0.0 mg Se/kg diet, 0.2 mg Se/kg diet, 2.0 mg 
Se/kg diet, 4.0 mg Se/kg diet) are separated by LPS and placebo groups to better show the interactive 
effect between diet and LPS.  Bars not sharing a common letter are significantly different from each other 
at p < 0.05.
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Discussion 
Se is considered an essential element for antioxidant enzymes such as glutathione 
peroxidase that catalyze the reduction of peroxides that can cause cellular damage [1].  Peroxides 
and other reactive oxygen species (ROS) generated through inflammation lead to damage of 
bone cellular matrix [2].   Smith and colleagues reported systemic bone loss due to 90-day time-
release pellets in male Sprague-Dawley rats [3].  Ishihara and coworker showed that LPS 
induced bone resorption in a BALB/c mouse calvaria organ culture [4].  The scavenging ability of 
Gpx has been shown to have a protective effect on cells against oxidative damage [5].  Dreher 
and colleagues reported antioxidative defense for human fetal osteoblasts that was mediated by 
expressed glutathione peroxidase [5].   
Se deficiency is associated with Kashin-Beck disease, a severe type of osteoarthritis [6].   
Rats supplemented with selenium showed less necrosis in the chondrocytes of the growth plates 
of tibia when compared to rats fed diets from Kashin-Beck disease endemic areas.  They also 
showed better BV/TV, trabecular thickness, and trabecular number, while trabecular separation 
was reduced [7].  Most of the literature examines the effect on bone of Se 
deficiency/supplementation and LPS inflammation separately.  To our knowledge, there is little 
research that investigates the effect of both Se status and chronic inflammation on bone loss, and 
the potential benefit of selenium supplementation.   
In this study second generation Se deficient mice were fed graded Se concentrations of 
0.02 (deficient), 0.2 (control/adequate), 2.0 and 4.0 mg Se/kg diet for 3 months and randomly 
assigned LPS treatment on 96-98 days of age to produce inflammatory stress.   The deficient diet 
(0.02 mg Se/kg) was well below daily requirements for rodents (0.1 mg Se/kg) [8] and the Se 
sufficient diet (0.2 mg Se/kg) was adequate [1].  Raines and Sunde reported no toxicity effect in 
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mice fed Se at 0.2 µg Se/g diet, but growth retardation (23%) was seen in rats fed 5 µg Se/g [9].  
High (relative to 0.1 mg Se/kg diet) but non-toxic Se intake for both mice and rats (less than 2 µg 
Se/g diet) showed little to no toxic effect [9]. 
Chronic inflammation due to LPS implantation (0.1 µg/g body weight/d) did not cause 
major changes to body or organ weights.  Body weight and organ weight data suggested that LPS 
treatment did not cause major undue stress and illness to the mice.  Body weight tended to 
decrease due to LPS treatment by the end of the study (d 120, p = 0.07).  A previous low-dose 
LPS model also showed non-significant body weight changes between LPS-treated and placebo 
groups [3].  Thymus weight, tended to be reduced by chronic inflammation (p = 0.06).   
Although changes were not seen in body parameters due to LPS, measurements of bone 
mineral showed that LPS had induced bone loss.  Bone densitometry in LPS-treated mice was 
significantly lowered when compared to placebo.  LPS-induced catabolic state in bone 
microarchitecture was primarily observed in trabecular bone as opposed to cortical bone 
indicating that trabecular bone is primarily affected by LPS-induced inflammation.  This result 
supports the notion that the detrimental effects observed with chronic LPS administration in the 
study were not a result of compromised animal health.  Cortical thinning in the lumbar vertebra 
has been observed in adjuvant models [10], but the slower rate of cortical bone turnover and the 
relatively low grade inflammation induced in this study may require a longer study duration to 
observe such changes.  The results of this study did indeed show a trend towards cortical bone 
damage in tibia under a condition of chronic inflammation. 
The bone loss seen through bone densitometry only reduced bone strength in spine, while 
the same was not seen in tibia.  LPS-induced inflammation did not show significant effects on 
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tibia biomechanics, but did in spine.  A higher turnover in vertebral bone compared to tibia could 
explain a significant LPS effect being only seen in spine [11].   
Taken separately, the dietary treatments at 0.0 mg/Se kg diet, 0.2 mg/Se kg diet, and 2.0 
mg/Se kg diet did not have negative health consequences.  A potential toxicity effect, however, 
was detected in the mice supplemented with 4.0 mg Se/kg diet.  Toxicity levels in rats have been 
reported at higher than 5.0 mg Se/kg diet [9] with LD50 of sodium selenate at 5.8 mg Se/kg diet 
[12].  Chronic Se levels in rats of 4-5 mg Se/kg have been reported to cause growth inhibition 
and tissue damage [13].  A 30 month dietary treatment of 0.5 – 2 mg Se/kg have shown liver 
toxicity in rats [14].  No severe health effects were recorded in the mice fed the 4.0 mg Se/kg 
diet, but some behavior oddities like sluggish response to feeding time were noticed.  The effects 
of added Se at 3.0 mg/Se kg diet could mitigate any health effects and dietary levels could still 
be still be high enough to see the effects of supplemented Se on a chronic inflammation model.   
Se adequate diets had mice with less dense bone compared to the other dietary 
treatments.  Bone mineral density (BMD) and bone mineral concentration (BMC) were higher in 
the Se deficient group (0.0 mg Se/kg diet) compared to the Se adequate group (0.2 mg Se/kg 
diet).  Se deficiency has been associated with reduced growth in animals [15].  Although the 
body parameters data do not show weight reduction due to dietary treatment, changes in bone 
might have occurred.  Relatively slow growth rate of mice in the Se deficient group could lead to 
increased bone mass and account for the higher bone densitometry when compared to Se 
adequate mice.  The mice in the selenium supplemented group (2.0 mg Se/kg diet and 4.0 mg 
Se/kg diet) had higher bone densitometry compared to the Se adequate mice.  These 
supplementary dietary treatments were 10 to 20 times higher than adequate for rodents [9] and 
are defined as being high levels that have been associated with less than optimal health in rats 
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[13].  The slowed growth seen though chronic dietary Se supplementation at ~4mg Se/kg diet 
[13] could have a similar effect to that of Se deficiency [15].  In our study, the dietary treatments 
were given to growing animals, and were not chronic as in previous literature, so any significant 
health damage may not yet have been visible.   
Se status was confirmed through measurement of Se concentration in liver tissue. As 
expected, liver Se content in mice fed the deficient diet was significantly lower than mice in the 
Se adequate group.  Se supplementation did not significantly increase liver Se content compared 
to control.  Organs like kidney and liver have very high levels of Se as a component of 
glutathione [16], levels of which have been shown to not be affected by Se supplementation [17].  
The Se concentration in liver was consistent with Burke and colleagues who reported liver 
selenium levels  at 0.1 µg/g in rats fed a low-selenium diet and at 0.7 µg/g in rats fed a selenium-
adequate diet [18].  Liver Se concentration in the Se adequate diet did not differ significantly 
from the Se supplemented groups most likely due to high variability within the diet group.  An 
increase in sample size might separate and better evaluate the differences.   
Bone microarchitecture parameters were relatively better in mice fed the Se deficient 
diet.  A different result was seen in rats supplemented with selenium compared to rats on a Se 
deficient diet [7].  Yao and coworkers compared the femur microarchitecture of Wistar rats on 
graded Se diets and found Se deficient diets to have lower quality bones [19].  Increased Se in 
the diet, however, did not show beneficial effects on trabecular bone.   
The biomechanical strength of tibia was significantly lower in mice fed Se adequate diet 
compared to the other dietary treatments as evidenced by stiffness being relatively low and von 
Mises measurements being comparatively high.  This is different from previously published 
work where Wistar rats fed selenium deficient or selenium-excess diets had decreased 
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biomechanical strength when compared to control [20].  In an induced diabetic animal model 
where Se was used as an antioxidant, rat mandible strength was weaker in the selenium 
supplemented control group when compared to the diabetic group supplemented with the same 
amount of Se [21].  Dellibasi and colleagues reported this finding as unexpected and 
recommended more studies into the mechanisms of  how Se affects organisms [21].   
Interactive effects between LPS and diet in measurements of tibia microarchitecture 
showed that dietary Se at adequate levels or above protected bone from the damage caused by 
LPS.   Connectivity density showed that the LPS effect of reducing trabecular bone was only 
significant in the Se deficient group.  No other dietary treatment group showed a significant 
difference between LPS-treated and placebo mice.  This supports that Se does provide anti-
oxidant protection from bone through glutathione peroxidase [1].  SMI similarly also showed 
significant difference only in the Se deficient group where LPS reduced the quality of bone.   
Interactive effects in biomechanical measurements of L4 spine, however, only show LPS 
effect in the Se adequate group.  Interactive effects of diet and LPS treatment did show increased 
strain and von Mises stress in the LPS treated Se adequate mice compared to placebo mice in the 
same dietary group. This could be explained by the remodeling process that is more active in 
spine than in peripheral bones [11], and vertebra has more chancellors bone and is thus more 
prone to bone alterations than in tibia.  More biomechanical testing such as bone-bending would 
be useful to have better understanding of this unexpected result. 
In conclusion, mice in the Se deficient group had higher quality bone microarchitecture 
when compared to the Se adequate mice, but the bone biomechanical testing showed that Se 
deficiency did not weaken bone as much as the recommended Se intake amount for mice.  
Protective effects from excess Se were also not observed.   
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CHAPTER V 
 
 
SUMMARY, CONCLUSIONS, AND SUGGESTIONS FOR FURTHER STUDY 
Summary 
 In this study we investigated the effects of selenium supplementation and chronic inflammation 
on bone microarchitecture and strength in mice.  To ascertain the Se status of the mice we assessed 
plasma and liver Se concentrations, and Gpx activity.  We assessed bone densitometry by PIXImus scans 
and microarchitecture and strength by microcomputed tomography.   
Se status   
Significant difference in Se status was only observed between the mice fed the basal diet and the 
Se supplemented groups as evidenced by Gpx activity and plasma and liver Se concentrations.   
Body parameters   
Chronic inflammation did not have a significant effect on body or organ weights, but bone 
density was reduced.  Mice on 0.0 mg, 0.2, and 2.0 mg added Se/kg diet did not show negative health 
effects as evidenced by organ weights (p > 0.05), but mice on 4.0 mg added Se/kg diet had reduced liver 
weight (p = 0.04) indicating possible toxicity.  Thymus weight tended to be increased by LSP (p = 0.06). 
Microarchitecture   
Overall, LPS induced chronic-inflammation weakened trabecular bone quality but not cortical 
bone.  LPS did not significantly increase cortical porosity or significantly reduced cortical thickness in 
tibia (p > 0.05).  Tibia and spine trabecular bone was reduced as shown by trabecular number 
and separation.  Interactive effects between diet and LPS in tibia trabecular measurements of 
SMI and connectivity density only showed the catabolic effect of LPS only in the mice fed the 
basal diet, indicating that Se supplementation beyond what is considered deficient does promote 
Gpx activity and provided protection against bone loss.   
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Bone Biomechanics 
Bone weakness due to LPS was seen in spine, but not in tibia.  The mice fed the Se adequate diet 
had comparatively weaker tibia than the mice in the other dietary treatments.  Spine strength 
measurements had several interactive effects, but stiffness was reduced by LPS treatment.  Interaction 
between LPS and diet showed the LPS effect of reducing bone strength was seen in mice fed the basal 
diet as evidenced by von mises and physiological force measurements.  The von Mises sress and strain 
measurements were also affected by LPS in the mice fed the Se adequate diet.  
Conclusions 
For this study we hypothesized: 
1. The inflammatory treatment would reduce bone quality/microarchitecture and strength.  Overall 
this effect of reducing bone microarchitecture was more pronounced in trabecular bone than 
cortical.  LPS reduced many trabecular bone parameters significantly, but only tended to reduced 
cortical bone.  Strength was not affected in tibia by LPS, and catabolic effects from inflammation 
were only seen in mice fed the basal and Se adequate diet.   
2. Higher dietary selenium will result in better microarchitecture parameters.  Our results did not 
support this hypothesis.  Overall, mice in the Se deficient diet had better microarchitecture 
compared to mice in the other dietary treatments.   
3. Higher dietary selenium will result in bone that is stronger.  Our results did not support this 
hypothesis.  Overall, mice in the Se adequate diet group had comparatively weaker tibia than 
mice in the other dietary treatments.  Spine strength measurements showed multiple interaction 
effects between LPS and diet.  LPS reduced bone strength measurements in the Se adequate and 
Se deficient mice only.   
Suggestions for Further Studies 
• Since our dietary treatment of 4.0 mg Se/kg diet reduced liver weight, a measurement of liver 
tissue damage makers like alanine amino transferase (ALT) would help determine the toxicity of 
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this dietary treatment.  If 4.0 mg Se/kg diet was potentially toxic, it would be interesting to see 
what effects a lower concentration of Se would have (e.g. 3.0 mg Se/kg diet).   
• Even though chronic inflammation did show bone damage through measurements of bone 
microarchitecture, lipid peroxidation assessment could have also established inflammatory status.  
Liver thiobarbituric acid reactive substances (TBARS) assessment is a common method used to 
determine lipid peroxidation.  In addition, antioxidant status could be determined by ferric 
reducing ability plasma (FRAP).  Bone metabolism could be determined by assessing 
biochemical markers such as alkaline phosphate (ALP), and serum tartrate resistant acid 
phosphatase (TRAP).  Osteocalcin could also be analyzed to determine bone formation.  This 
could help better determine exactly how LPS reduced bone quality:  through increase of bone 
loss, or disruption of bone formation, or both.   
• To better understand the effects of dietary treatments on bone strength, bone biomechanical 
testing using 3-point bending could provide more information to better interpret the results we 
had.   
• To determine if the dietary treatments did cause growth retardation, it would be useful to measure 
femur or tibia length, and ash the bones to look at weight.   
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Scope and Method of Study:  The effects of dietary Se and lipopolysaccharide (LPS)-induced  
inflammation on microarchitecture and strength of bone were investigated in C57BL/6 mice.  
Timed-pregnant mice were fed a Torula yeast selenium-depletion diet from the final days of 
gestation through lactation.  At 23 days of age, pups were weaned and randomly assigned to the 
depletion diet or to diets supplemented with a 0.2, 2 or 4 mg/kg diet of Se added as sodium 
selenate for 14 weeks.  At 96 – 98 days of age mice were randomly assigned to placebo or to 
lipopolysaccharide (E. coli Serotype 0127:B8) treatment to produce chronic inflammation.  Time 
release pellets (0 or 0.1 µg/g body weight/d) were implanted subcutaneously.  Mice were killed at 
120 days of age after an overnight fast.  Bone densitometry and organ and body weights were 
used to determine health status.  Se status was assessed through Gpx3 activity, and plasma and 
liver Se concentration.  Micro-CT was used to assess trabecular bone of the fourth lumbar 
vertebra (L4) and trabecular and cortical bone of tibia.  Using finite element analysis a simulated 
compression test in the z direction was used to assess strength of trabecular cores.   
 
Findings and Conclusions:  Low dose inflammation did not cause significant loss of body weight by 
necropsy, but LPS tended to increase thymus weight (p = 0.06).  Reduced BMD and BMC 
showed a catabolic state due to LPS (p = 0.02).  LPS-treatment tended (p = 0.06) to reduced tibia 
cortical thickness and increase cortical porosity (p = 0.07), while significantly reducing many 
parameters of trabecular bone.  Inflammation tended (p = 0.07) to increase von Mises stress in 
tibia trabecular bone, and significantly reduced stiffness in L4.  GPx3 activity as well as plasma 
and liver Se concentration were significantly higher in the Se adequate group than in the Se 
deficient group, but didn’t differ significantly from mice in the highly supplemented groups.  
Liver weight was significantly reduced in the 4 mg Se/kg group indicating possible toxicity.  
Contrary to our hypothesis, tibia and L4 trabecular bone parameters in Se deficient mice were 
significantly improved compared to Se adequate mice and compared with the Se supplemented 
groups.  Tibia biomechanical measurements showed physiological force (p = 0.04) and stiffness 
(p = 0.04) to be higher, and von Mises stress (0.0001) to be lower in the Se deficient, 2.0 mg/kg 
and 2.0 mg/kg compared to the Se adequate mice.  Interactive effects between LPS and diet in 
tibial connectivity density and SMI showed LPS to reduce bone strength only in the Se deficient 
group.  Interactions between diet and LPS in average apparent strain, physiological force and von 
Mises stress of L4 also showed catabolic LPS effects only in the Se deficient and Se adequate 
groups.  Further study in the mechanism of Se action in growing animals needs to be conducted to 
better explain these results.   
 
 
 
 
 
